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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/
doi/10.1111/bph.13350/full. Ligand-gated ion channels are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-
gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the
best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification
and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable,
point-in-time record that will survive database updates.
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Overview: Ligand-gated ion channels (LGICs) are integral mem-
brane proteins that contain a pore which allows the regulated
flow of selected ions across the plasma membrane. Ion flux is
passive and driven by the electrochemical gradient for the per-
meant ions. These channels are open, or gated, by the binding of
a neurotransmitter to an orthosteric site(s) that triggers a confor-
mational change that results in the conducting state. Modulation
of gating can occur by the binding of endogenous, or exogenous,
modulators to allosteric sites. LGICs mediate fast synaptic trans-
mission, on a millisecond time scale, in the nervous system and
at the somatic neuromuscular junction. Such transmission in-
volves the release of a neurotransmitter from a pre-synaptic neu-
rone and the subsequent activation of post-synaptically located
receptors that mediate a rapid, phasic, electrical signal (the ex-
citatory, or inhibitory, post-synaptic potential). However, in ad-
dition to their traditional role in phasic neurotransmission, it is
now established that some LGICs mediate a tonic form of neu-
ronal regulation that results from the activation of extra-synaptic
receptors by ambient levels of neurotransmitter. The expression
of some LGICs by non-excitable cells is suggestive of additional
functions.
By convention, the LGICs comprise the excitatory, cation-
selective, nicotinic acetylcholine [48, 236], 5-HT3 [20, 353],
ionotropic glutamate [208, 338] and P2X receptors [158, 321] and
the inhibitory, anion-selective, GABAA [25, 264] and glycine re-
ceptors [215, 373]. The nicotinic acetylcholine, 5-HT3, GABAA
and glycine receptors (and an additional zinc-activated channel)
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are pentameric structures and are frequently referred to as the
Cys-loop receptors due to the presence of a defining loop of
residues formed by a disulphide bond in the extracellular domain
of their constituent subunits [238, 327]. However, the prokary-
otic ancestors of these receptors contain no such loop and the
term pentameric ligand-gated ion channel (pLGIC) is gaining ac-
ceptance in the literature [133]. The ionotropic glutamate and
P2X receptors are tetrameric and trimeric structures, respectively.
Multiple genes encode the subunits of LGICs and the majority of
these receptors are heteromultimers. Such combinational diver-
sity results, within each class of LGIC, in a wide range of recep-
tors with differing pharmacological and biophysical properties
and varying patterns of expression within the nervous system
and other tissues. The LGICs thus present attractive targets for
new therapeutic agents with improved discrimination between
receptor isoforms and a reduced propensity for off-target effects.
The development of novel, faster screening techniques for com-
pounds acting on LGICs [88] will greatly aid in the development
of such agents.
Family structure
5871 5-HT3 receptors
5873 Acid-sensing (proton-gated) ion channels (ASICs)
5875 Epithelial sodium channels (ENaC)
5877 GABAA receptors
5882 Glycine receptors
5885 Ionotropic glutamate receptors
5891 IP3 receptor
5892 Nicotinic acetylcholine receptors
5896 P2X receptors
5898 Ryanodine receptor
5900 ZAC
5-HT3 receptors
Ligand-gated ion channels! 5-HT3 receptors
Overview: The 5-HT3 receptor (nomenclature as
agreed by the NC-IUPHAR Subcommittee on 5-
Hydroxytryptamine (serotonin) receptors [145]) is a
ligand-gated ion channel of the Cys-loop family that includes
the zinc-activated channels, nicotinic acetylcholine, GABAA and
strychnine-sensitive glycine receptors. The receptor exists as a
pentamer of 4TM subunits that form an intrinsic cation selective
channel [20]. Five human 5-HT3 receptor subunits have been
cloned and homo-oligomeric assemblies of 5-HT3A and hetero-
oligomeric assemblies of 5-HT3A and 5-HT3B subunits have been
characterised in detail. The 5-HT3C (HTR3C, Q8WXA8), 5-HT3D
(HTR3D, Q70Z44) and 5-HT3E (HTR3E, A5X5Y0) subunits [173,
256], like the 5-HT3B subunit, do not form functional homo-
mers, but are reported to assemble with the 5-HT3A subunit to
influence its functional expression rather than pharmacological
profile [136, 258, 352]. 5-HT3A, -C, -D, and -E subunits also in-
teract with the chaperone RIC-3 which predominantly enhances
the surface expression of homomeric 5-HT3A receptor [352].
The co-expression of 5-HT3A and 5-HT3C-E subunits has been
demonstrated in human colon [170]. A recombinant hetero-
oligomeric 5-HT3AB receptor has been reported to contain two
copies of the 5-HT3A subunit and three copies of the 5-HT3B
subunit in the order B-B-A-B-A [23], but this is inconsistent with
recent reports which show at least one A-A interface [207, 331].
The 5-HT3B subunit imparts distinctive biophysical properties
upon hetero-oligomeric 5-HT3AB versus homo-oligomeric 5-
HT3A recombinant receptors [68, 86, 124, 160, 178, 277, 317],
influences the potency of channel blockers, but generally has
only a modest effect upon the apparent affinity of agonists, or
the affinity of antagonists ([36], but see [67, 71, 86]) which may
be explained by the orthosteric binding site residing at an in-
terface formed between 5-HT3A subunits [207, 331]. However,
5-HT3A and 5-HT3AB receptors differ in their allosteric regu-
lation by some general anaesthetic agents, small alcohols and
indoles [146, 293, 314]. The potential diversity of 5-HT3 recep-
tors is increased by alternative splicing of the genes HTR3A and
E [39, 139, 255, 257, 258]. In addition, the use of tissue-specific
promoters driving expression from different transcriptional start
sites has been reported for theHTR3A, HTR3B,HTR3D and HTR3E
genes, which could result in 5-HT3 subunits harbouring differ-
ent N-termini [160, 255, 339]. To date, inclusion of the 5-HT3A
subunit appears imperative for 5-HT3 receptor function.
Nomenclature 5-HT3AB 5-HT3A
Subunits 5-HT3A, 5-HT3B 5-HT3A
Functional Characteristics γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly rectifying current [+ 5-HT3B,
rectification reduced]; nH 2-3 [+ 5-HT3B 1-2]; relative permeability to divalent
cations reduced by co-expression of the 5-HT3B subunit
γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly rectifying current [+ 5-HT3B,
rectification reduced]; nH 2-3 [+ 5-HT3B 1-2]; relative permeability to divalent
cations reduced by co-expression of the 5-HT3B subunit
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(continued)
Nomenclature 5-HT3AB 5-HT3A
Selective agonists – meta-chlorphenylbiguanide (pEC50 5.4–5.8) [24, 68, 196, 241, 242],
2-methyl-5-HT (pEC50 5.5–5.6) [24, 68, 196, 241], SR57227A (pEC50 5.4) [90] –
Rat, 1-phenylbiguanide (pEC50 4.1) [24]
Antagonists – vortioxetine (pKi 8.4) [17], metoclopramide (pKi 6–6.4) [36, 140]
Selective antagonists – palonosetron (pKi 10.5) [248], alosetron (pKi 9.5) [134], (S)-zacopride (pKi 9)
[36], granisetron (pKi 8.6–8.8) [140, 241], tropisetron (pKi 8.5–8.8) [196,
241], ondansetron (pKi 7.8–8.3) [36, 140, 241]
Channel blockers picrotoxinin (pIC50 4.2) [326], bilobalide (pIC50 2.5) [326], ginkgolide B (pIC50
2.4) [326]
picrotoxinin (pIC50 5) [325], TMB-8 (pIC50 4.9) [320], diltiazem (pIC50 4.7)
[325], bilobalide (pIC50 3.3) [325], ginkgolide B (pIC50 3.1) [325]
Labelled ligands – [3H]ramosetron (Antagonist) (pKd 9.8) [241], [
3H]GR65630 (Antagonist) (pKd
8.6–9.3) [134, 196], [3H]granisetron (Antagonist) (pKd 8.9) [36, 140],
[3H](S)-zacopride (Antagonist) (pKd 8.7) [271], [
3H]LY278584 (Antagonist)
(pKd 8.5) [2]
Subunits
Nomenclature 5-HT3A 5-HT3B 5-HT3C 5-HT3D 5-HT3E
HGNC, UniProt HTR3A, P46098 HTR3B, O95264 HTR3C, Q8WXA8 HTR3D, Q70Z44 HTR3E,
A5X5Y0
Functional Characteristics γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly
rectifying current [+ 5-HT3B, rectification reduced];
nH 2-3 [+ 5-HT3B 1-2]; relative permeability to
divalent cations reduced by co-expression of the
5-HT3B subunit
γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly
rectifying current [+ 5-HT3B, rectification reduced];
nH 2-3 [+ 5-HT3B 1-2]; relative permeability to
divalent cations reduced by co-expression of the
5-HT3B subunit
– – –
Comments: Quantitative data in the table refer to homo-
oligomeric assemblies of the human 5-HT3A subunit, or the
receptor native to human tissues. Significant changes intro-
duced by co-expression of the 5-HT3B subunit are indicated in
parenthesis. Although not a selective antagonist, methadone
displays multimodal and subunit-dependent antagonism of 5-
HT3 receptors [71]. Similarly, TMB-8, diltiazem, picrotoxin,
bilobalide and ginkgolide B are not selective for 5-HT3 recep-
tors (e.g.[326]). The anti-malarial drugs mefloquine and quinine
exert a modestly more potent block of 5-HT3A versus 5-HT3AB
receptor-mediated responses [328]. Known better as a partial ago-
nist of nicotinic acetylcholine α4β2 receptors, varenicline is also
an agonist of the 5-HT3A receptor [213]. Human [24, 241], rat
[151], mouse [224], guinea-pig [196] ferret [243] and canine [162]
orthologues of the 5-HT3A receptor subunit have been cloned
that exhibit intraspecies variations in receptor pharmacology.
Notably, most ligands display significantly reduced affinities at
the guinea-pig 5-HT3 receptor in comparison with other species.
In addition to the agents listed in the table, native and recombi-
nant 5-HT3 receptors are subject to allosteric modulation by ex-
tracellular divalent cations, alcohols, several general anaesthetics
and 5-hydroxy- and halide-substituted indoles (see reviews [272,
329, 330, 353]).
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Acid-sensing (proton-gated) ion channels (ASICs)
Ligand-gated ion channels! Acid-sensing (proton-gated) ion channels (ASICs)
Overview: Acid-sensing ion channels (ASICs, nomenclature
as agreed by NC-IUPHAR [177]) are members of a Na+ chan-
nel superfamily that includes the epithelial Na+ channel (ENaC),
the FMRF-amide activated channel (FaNaC) of invertebrates, the
degenerins (DEG) of Caenorhabitis elegans, channels in Drosophila
melanogaster and ‘orphan’ channels that include BLINaC [294]
and INaC [297]. ASIC subunits contain two TM domains and
assemble as homo- or hetero-trimers [114, 159] to form proton-
gated, voltage-insensitive, Na+ permeable, channels (reviewed in
[119]). Splice variants of ASIC1 [provisionally termed ASIC1a
(ASIC, ASICα, BNaC2α) [349], ASIC1b (ASICβ, BNaC2β) [54]
and ASIC1b2 (ASICβ2) [340]; note that ASIC1a is also perme-
able to Ca2+] and ASIC2 [provisionally termed ASIC2a (MDEG1,
BNaC1α, BNC1α) [109, 284, 350] and ASIC2b (MDEG2, BNaC1β)
[205]] have been cloned. Unlike ASIC2a (listed in table), het-
erologous expression of ASIC2b alone does not support H+-gated
currents. A third member, ASIC3 (DRASIC, TNaC1) [348], has
been identified. A fourth mammalian member of the family
(ASIC4/SPASIC) does not support a proton-gated channel in het-
erologous expression systems and is reported to down regulate
the expression of ASIC1a and ASIC3 [5, 80, 120]. ASIC chan-
nels are primarily expressed in central and peripheral neurons
including nociceptors where they participate in neuronal sen-
sitivity to acidosis. They have also been detected in taste re-
ceptor cells (ASIC1-3), photoreceptors and retinal cells (ASIC1-
3), cochlear hair cells (ASIC1b), testis (hASIC3), pituitary gland
(ASIC4), lung epithelial cells (ASIC1a and -3), urothelial cells,
adipose cells (ASIC3), vascular smooth muscle cells (ASIC1-3),
immune cells (ASIC1,-3 and -4) and bone (ASIC1-3). The acti-
vation of ASIC1a within the central nervous system contributes
to neuronal injury caused by focal ischemia [364] and to axonal
degeneration in autoimmune inflammation in a mouse model of
multiple sclerosis [102]. However, activation of ASIC1a can termi-
nate seizures [382]. Peripheral ASIC3-containing channels play a
role in post-operative pain [74]. Further proposed roles for cen-
trally and peripherally located ASICs are reviewed in [357] and
[203]. The relationship of the cloned ASICs to endogenously ex-
pressed proton-gated ion channels is becoming established [78,
79, 94, 126, 203, 204, 322, 355, 356, 357]. Heterologously ex-
pressed heteromultimers form ion channels with altered kinet-
ics, ion selectivity, pH- sensitivity and sensitivity to blockers that
resemble some of the native proton activated currents recorded
from neurones [15, 22, 94, 205].
Nomenclature ASIC1 ASIC2 ASIC3
HGNC, UniProt ASIC1, P78348 ASIC2, Q16515 ASIC3, Q9UHC3
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(continued)
Nomenclature ASIC1 ASIC2 ASIC3
Functional Characteristics ASIC1a: γ 14pS
PNa/PK = 5-13, PNa/PCa =2.5
rapid activation rate (5.8-13.7 ms), rapid
inactivation rate (1.2-4 s) @ pH 6.0, slow
recovery (5.3-13s) @ pH 7.4
ASIC1b: γ 19 pS
PNa/PK =14.0, PNa  PCa
rapid activation rate (9.9 ms), rapid inactivation
rate (0.9-1.7 s) @ pH 6.0, slow recovery (4.4-7.7
s) @ pH 7.4
γ 10.4-13.4 pS
PNa/PK =10, PNa/PCa = 20
rapid activation rate, moderate inactivation rate
(3.3-5.5 s) @ pH 5
γ 13-15 pS;
biphasic response consisting of rapidly
inactivating transient and sustained
components;
very rapid activation (<5 ms) and inactivation
(0.4 s);
fast recovery (0.4-0.6 s) @ pH 7.4, transient
component partially inactivated at pH 7.2
Endogenous activators Extracellular H+ (ASIC1a) (pEC50 6.2–6.8),
Extracellular H+ (ASIC1b) (pEC50 5.1–6.2)
Extracellular H+ (pEC50 4.1–5) Extracellular H+ (transient component) (pEC50
6.2–6.7), Extracellular H+ (sustained
component) (pEC50 3.5–4.3)
Activators – – GMQ (largly non-desensitizing; at pH 7.4)
(pEC50 3), arcaine (at pH 7.4) (pEC50 2.9),
agmatine (at pH 7.4) (pEC50 2)
Channel blockers psalmotoxin 1 (ASIC1a) (pIC50 9), Zn2+ (ASIC1a)
(pIC50 8.2), Pb2+ (ASIC1b) (pIC50 5.8),
A-317567 (ASIC1a) (pIC50 5.7) [87] – Rat, Pb2+
(ASIC1a) (pIC50 5.4), amiloride (ASIC1a) (pIC50
5), benzamil (ASIC1a) (pIC50 5),
ethylisopropylamiloride (ASIC1a) (pIC50 5),
nafamostat (ASIC1a) (pIC50 4.9), amiloride
(ASIC1b) (pIC50 4.6–4.7), flurbiprofen (ASIC1a)
(pIC50 3.5) [345] – Rat, ibuprofen (ASIC1a)
(pIC50 3.5), Ni2+ (ASIC1a) (pIC50 3.2)
amiloride (pIC50 4.6), A-317567 (pIC50 4.5),
nafamostat (pIC50 4.2), Cd2+ (pIC50 3)
APETx2 (transient component only) (pIC50 7.2),
nafamostat (transient component) (pIC50
5.6), A-317567 (pIC50 5), amiloride
(transient component only - sustained
component enhanced by 200M amiloride at
pH 4) (pIC50 4.2–4.8), Gd3+ (pIC50 4.4), Zn2+
(pIC50 4.2), aspirin (sustained component)
(pIC50 4) [345], diclofenac (sustained
component) (pIC50 4), salicylic acid (sustained
component) (pIC50 3.6)
Labelled ligands [125I]psalmotoxin 1 (ASIC1a) (pKd 9.7) – –
Comments ASIC1a and ASIC1b are also blocked by
diarylamidines (IC50 3 M for ASIC1a)
ASIC2 is also blocked by diarylamidines ASIC3 is also blocked by diarylamidines
Comments: psalmotoxin 1 (PcTx1) inhibits ASIC1a by modify-
ing activation and desensitization by H+, but promotes ASIC1b
opening. PcTx1 has little effect upon ASIC2a, ASIC3, or ASIC1a
expressed as a heteromultimer with either ASIC2a, or ASIC3 [79,
94] but does block ASIC1a expressed as a heteromultimer with
ASIC2b [304]. Spermine, which apparently competes with PcTx1
for binding to ASIC1a, selectively enhances the function of the
channel [85]. Blockade of ASIC1a by PcTx1 activates the en-
dogenous enkephalin pathway and has very potent analgesic
effects in rodents [228]. APETx2 most potently blocks homo-
meric ASIC3 channels, but also ASIC2b+ASIC3, ASIC1b+ASIC3,
and ASIC1a+ASIC3 heteromeric channels with IC50 values of 117
nM, 900 nM and 2 M, respectively. APETx2 has no effect on
ASIC1a, ASIC1b, ASIC2a, or ASIC2a+ASIC3 [78, 79]. IC50 val-
ues for A-317567 are inferred from blockade of ASIC channels
native to dorsal root ganglion neurones [87]. The pEC50 values
for proton activation of ASIC channels are influenced by numer-
ous factors including extracellular di- and poly-valent ions, Zn2+,
protein kinase C and serine proteases (reviewed in [204]). Rapid
acidification is required for activation of ASIC1 and ASIC3 due to
fast inactivation/desensitization. pEC50 values for H
+-activation
of either transient, or sustained, currents mediated by ASIC3 vary
in the literature and may reflect species and/or methodological
differences [16, 348, 383]. The transient and sustained current
components mediated by rASIC3 are selective for Na+ [348]; for
hASIC3 the transient component is Na+ selective (PNa/PK > 10)
whereas the sustained current appears non-selective (PNa/PK =
1.6) [16, 383]. The reducing agents dithiothreitol (DTT) and glu-
tathione (GSH) increase ASIC1a currents expressed in CHO cells
and ASIC-like currents in sensory ganglia and central neurons
[9, 59] whereas oxidation, through the formation of intersubunit
disulphide bonds, reduces currents mediated by ASIC1a [379].
ASIC1a is also irreversibly modulated by extracellular serine pro-
teases, such as trypsin, through proteolytic cleavage [346]. Non-
steroidal anti-inflammatory drugs (NSAIDs) are direct blockers of
ASIC currents at therapeutic concentrations (reviewed in [344]).
Extracellular Zn2+ potentiates proton activation of homomeric
and heteromeric channels incorporating ASIC2a, but not homo-
meric ASIC1a or ASIC3 channels [21]. However, removal of con-
taminating Zn2+ by chealation reveals a high affinity block of
homomeric ASIC1a and heteromeric ASIC1a+ASIC2 channels by
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Zn2+ indicating complex biphasic actions of the divalent [60].
Nitric oxide potentiates submaximal currents activated by H+
mediated by ASIC1a, ASIC1b, ASIC2a and ASIC3 [42]. Ammo-
nium activates ASIC channels (most likely ASIC1a) in midbrain
dopaminergic neurones: that may be relevant to neuronal disor-
ders associated with hyperammonemia [278]. The positive mod-
ulation of homomeric, heteromeric and native ASIC channels
by the peptide FMRFamide and related substances, such as neu-
ropeptides FF and SF, is reviewed in detail in [204]. Inflamma-
tory conditions and particular pro-inflammatory mediators in-
duce overexpression of ASIC-encoding genes, enhance ASIC cur-
rents [223], and in the case of arachidonic acid directly activate
the channel [75, 310]. The sustained current component medi-
ated by ASIC3 is potentiated by hypertonic solutions in a manner
that is synergistic with the effect of arachidonic acid [75]. Se-
lective activation of ASIC3 by GMQ at a site separate from the
proton binding site is potentiated by mild acidosis and reduced
extracellular Ca2+ [376].
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Epithelial sodium channels (ENaC)
Ligand-gated ion channels! Epithelial sodium channels (ENaC)
Overview: The epithelial sodium channels (ENaC) mediates
sodium reabsorption in the aldosterone-sensitive distal part of
the nephron and the collecting duct of the kidney. ENaC is found
on other tight epithelial tissues such as the airways, distal colon
and exocrine glands. ENaC activity is tightly regulated in the kid-
ney by aldosterone, angiotensin II ( AGT, P01019), vasopressin
( AVP, P01185), insulin ( INS, P01308) and glucocorticoids; this
fine regulation of ENaC is essential to maintain sodium balance
between daily intake and urinary excretion of sodium, circulat-
ing volume and blood pressure. ENaC expression is also vital for
clearance of foetal lung fluid, and to maintain air-surface-liquid
[147, 209]. Sodium reabsorption is suppressed by the ‘potassium-
sparing’ diuretics amiloride and triamterene. ENaC is a hetero-
multimeric channel made of homologous α β and γ subunits. The
primary structure of αENaC subunit was identified by expression
cloning [43]; β and γ ENaC were identified by functional comple-
mentation of the α subunit [44]. Each ENaC subunit contains 2
TM α helices connected by a large extracellular loop and short
cytoplasmic amino- and carboxy-termini. The stoichiometry of
the epithelial sodium channel in the kidney and related epithe-
lia is, by homology with the structurally related channel ASIC1a,
thought to be a heterotrimer of 1α:1β:1γ subunits [114].
Nomenclature ENaCαβγ
Subunits ENaC β, ENaC α, ENaC γ
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Functional Characteristics γ  4-5 pS, PNa/PK > 20; tonically open at rest; expression and ion flux regulated by circulating aldosterone-mediated changes in gene transcription. The action of
aldosterone, which occurs in ‘early’ (1.5-3 h) and ‘late’ (6-24 hr) phases is competitively antagonised by spironolactone, its active metabolites and eplerenone.
Glucocorticoids are important functional regulators in lung/airways and this control is potentiated by thyroid hormone; but the mechanism underlying such potentiation
is unclear [18, 287, 296]. The density of channels in the apical membrane, and hence GNa, can be controlledvia both serum and glucocorticoid-regulated kinases (SGK1,
2 and 3) [70, 101] and via cAMP/PKA [246]; and these protein kinases appear to act by inactivating Nedd-4/2, a ubiquitin ligase that normally targets the ENaC channel
complex for internalization and degradation [31, 70]. ENaC is constitutively activated by soluble and membrane-bound serine proteases, such as furin, prostasin (CAP1),
plasmin and elastase [186, 187, 281, 289, 290]. The activation of ENaC by proteases is blocked by a protein, SPLUNC1, secreted by the airways and which binds
specifically to ENaC to prevent its cleavage [108]. Pharmacological inhibitors of proteases (e.g. camostat acting upon prostasin) reduce the activity of ENaC [219].
Phosphatidylinositides such as PtIns(4,5)P2 and PtIns(3,4,5)P3) stabilise channel gating probably by binding to the β and γ ENaC subunits, respectively [217, 283], whilst
C terminal phosphorylation of β and γ-ENaC by ERK1/2 has been reported to inhibit the withdrawal of the channel complex from the apical membrane [367]. This effect
may contribute to the cAMP-mediated increase in sodium conductance.
Activators S3969 (pEC50 5.9) [211]
Channel blockers P552-02 (pIC50 8.1), benzamil (pIC50 8), amiloride (pIC50 6.7–7), triamterene (pIC50 5.3) [44, 176]
Comments: Data in the table refer to the αβγ heteromer. There
are several human diseases resulting from mutations in ENaC
subunits. Liddle’s syndrome (including features of salt-sensitive
hypertension and hypokalemia), is associated with gain of func-
tion mutations in the β and γ subunits leading to defective ENaC
ubiquitylation and increased stability of active ENaC at the cell
surface [290, 298, 316]. Enzymes that deubiquitylate ENaC in-
crease its function in vivo. Pseudohypoaldosteronism type 1
(PHA-1) can occur through eithermutations in the gene encoding
the mineralocorticoid receptor, or loss of function mutations in
genes encoding ENaC subunits [34]. Regulation of ENaC by phos-
phoinositides may underlie insulin ( INS, P01308)-evoked renal
Na+ retention that can complicate the clinical management of
type 2 diabetes using insulin-sensitizing thiazolidinedione drugs
[121].
Subunits
Nomenclature ENaC α ENaC β ENaC Æ ENaC γ
HGNC, UniProt SCNN1A, P37088 SCNN1B, P51168 SCNN1D, P51172 SCNN1G, P51170
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GABAA receptors
Ligand-gated ion channels! GABAA receptors
Overview: The GABAA receptor is a ligand-gated ion channel
of the Cys-loop family that includes the nicotinic acetylcholine,
5-HT3 and strychnine-sensitive glycine receptors. GABAA
receptor-mediated inhibition within the CNS occurs by fast
synaptic transmission, sustained tonic inhibition and temporally
intermediate events that have been termed ‘GABAA, slow’ [45].
GABAA receptors exist as pentamers of 4TM subunits that form
an intrinsic anion selective channel. Sequences of six α, three
β, three γ, one Æ, three , one , one  and one  GABAA re-
ceptor subunits have been reported in mammals [263, 264, 305,
307]. The -subunit is restricted to reproductive tissue. Alter-
natively spliced versions of many subunits exist (e.g. α4- and
α6- (both not functional) α5-, β2-, β3- and γ2), along with RNA
editing of the α3 subunit [66]. The three -subunits, (1-3) func-
tion as either homo- or hetero-oligomeric assemblies [53, 380].
Receptors formed from -subunits, because of their distinctive
pharmacology that includes insensitivity to bicuculline, benzodi-
azepines and barbiturates, have sometimes been termed GABAC
receptors [380], but they are classified as GABAA receptors
by NC-IUPHAR on the basis of structural and functional
criteria [19, 263, 264].
Many GABAA receptor subtypes contain α-, β- and γ-subunits
with the likely stoichiometry 2α.2β.1γ [190, 264]. It is thought
that the majority of GABAA receptors harbour a single type of
α- and β -subunit variant. The α1β2γ2 hetero-oligomer consti-
tutes the largest population of GABAA receptors in the CNS, fol-
lowed by the α2β3γ2 and α3β3γ2 isoforms. Receptors that incor-
porate the α4- α5-or α6-subunit, or the β1-, γ1-, γ3-, Æ-, - and
-subunits, are less numerous, but they may nonetheless serve
important functions. For example, extrasynaptically located re-
ceptors that contain α6- and Æ-subunits in cerebellar granule cells,
or an α4- and Æ-subunit in dentate gyrus granule cells and thala-
mic neurones, mediate a tonic current that is important for neu-
ronal excitability in response to ambient concentrations of GABA
[25, 96, 244, 301, 311]. GABA binding occurs at the β+/α- sub-
unit interface and the homologous γ+/α- subunits interface cre-
ates the benzodiazepine site. A second site for benzodiazepine
binding has recently been postulated to occur at the α+/β- inter-
face ([286]; reviewed by [306]). The particular α-and γ-subunit
isoforms exhibit marked effects on recognition and/or efficacy at
the benzodiazepine site. Thus, receptors incorporating either α4-
or α6-subunits are not recognised by ‘classical’ benzodiazepines,
such as flunitrazepam (but see [374]). The trafficking, cell sur-
face expression, internalisation and function of GABAA receptors
and their subunits are discussed in detail in several recent reviews
[58, 153, 214, 343] but one point worthy of note is that receptors
incorporating the γ2 subunit (except when associated with α5)
cluster at the postsynapticmembrane (butmay distribute dynam-
ically between synaptic and extrasynaptic locations), whereas as
those incorporating the d subunit appear to be exclusively ex-
trasynaptic.
NC-IUPHAR [19, 264] class the GABAA receptors according
to their subunit structure, pharmacology and receptor function.
Currently, eleven native GABAA receptors are classed as conclu-
sively identified (i.e., α1β2γ2, α1βγ2, α3βγ2, α4βγ2, α4β2Æ, α4β3Æ,
α5βγ2, α6βγ2, α6β2Æ, α6β3Æ and ) with further receptor isoforms
occurring with high probability, or only tentatively [263, 264]. It
is beyond the scope of this Guide to discuss the pharmacology
of individual GABAA receptor isoforms in detail; such informa-
tion can be gleaned in the reviews [19, 104, 165, 190, 192, 249,
263, 264, 305] and [11, 12]. Agents that discriminate between α-
subunit isoforms are noted in the table and additional agents that
demonstrate selectivity between receptor isoforms, for example
via β-subunit selectivity, are indicated in the text below. The dis-
tinctive agonist and antagonist pharmacology of  receptors is
summarised in the table and additional aspects are reviewed in
[53, 166, 253, 380].
Nomenclature GABAA receptor α1 subunit GABAA receptor α2 subunit GABAA receptor α3 subunit
HGNC, UniProt GABRA1, P14867 GABRA2, P47869 GABRA3, P34903
Agonists gaboxadol [GABA site], isoguvacine [GABA site],
isonipecotic acid [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site],
isonipecotic acid [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site],
isonipecotic acid [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site]
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Nomenclature GABAA receptor α1 subunit GABAA receptor α2 subunit GABAA receptor α3 subunit
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric
modulators
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition), tetrahydrodeoxycorticosterone (Potentiation)
Nomenclature GABAA receptor α1 subunit GABAA receptor α2 subunit GABAA receptor α3 subunit
Allosteric modulators clonazepam (Positive) (pKi 8.9) [285], flunitrazepam
[benzodiazepine site] (Positive) (pKi 8.3) [122],
diazepam [benzodiazepine site] (Positive) (pKi 7.8)
[285], alprazolam [benzodiazepine site] (Positive)
(pEC50 7.4) [6], α3IA [benzodiazepine site] (Inverse
agonist), α5IA [benzodiazepine site] (Inverse agonist),
DMCM [benzodiazepine site] (Inverse agonist), MRK016
[benzodiazepine site] (Inverse agonist), RO4938581
[benzodiazepine site] (Inverse agonist), Ro15-4513
[benzodiazepine site] (Inverse agonist), Ro19-4603
[benzodiazepine site] (Inverse agonist), TP003
[benzodiazepine site] (Antagonist), TPA023
[benzodiazepine site] (Antagonist), bretazenil
[benzodiazepine site] (Full agonist), flumazenil
[benzodiazepine site] (Antagonist)
clonazepam (Positive) (pKi 8.8) [285], flunitrazepam
[benzodiazepine site] (Positive) (pKi 8.3) [122],
alprazolam [benzodiazepine site] (Positive) (pEC50 7.9)
[6], diazepam [benzodiazepine site] (Positive) (pKi 7.8)
[285], α3IA [benzodiazepine site] (Inverse agonist), α5IA
[benzodiazepine site] (Inverse agonist), DMCM
[benzodiazepine site] (Inverse agonist), MRK016
[benzodiazepine site] (Inverse agonist), RO4938581
[benzodiazepine site] (Inverse agonist), Ro15-4513
[benzodiazepine site] (Inverse agonist), Ro19-4603
[benzodiazepine site] (Inverse agonist), TP003
[benzodiazepine site] (Antagonist), ZK93426
[benzodiazepine site] (Antagonist), bretazenil
[benzodiazepine site] (Full agonist), flumazenil
[benzodiazepine site] (Antagonist), ocinaplon
[benzodiazepine site] (Partial agonist)
clonazepam (Positive) (pKi 8.7) [285], flunitrazepam
[benzodiazepine site] (Positive) (pKi 7.8) [122],
diazepam [benzodiazepine site] (Positive) (pKi 7.8)
[285], alprazolam [benzodiazepine site] (Positive)
(pEC50 7.2) [6], α5IA [benzodiazepine site] (Inverse
agonist), DMCM [benzodiazepine site] (Inverse agonist),
MRK016 [benzodiazepine site] (Inverse agonist),
RO4938581 [benzodiazepine site] (Inverse agonist),
Ro15-4513 [benzodiazepine site] (Inverse agonist),
ZK93426 [benzodiazepine site] (Antagonist), bretazenil
[benzodiazepine site] (Full agonist), flumazenil
[benzodiazepine site] (Antagonist), ocinaplon
[benzodiazepine site] (Partial agonist)
Selective allosteric
modulators
zolpidem (Positive) (pKi 7.4–7.7) [123, 299], L838417
[benzodiazepine site] (Antagonist), ZK93426
[benzodiazepine site] (Antagonist), indiplon
[benzodiazepine site] (Full agonist), ocinaplon
[benzodiazepine site] (Full agonist)
L838417 [benzodiazepine site] (Partial agonist), TPA023
[benzodiazepine site] (Partial agonist)
α3IA [benzodiazepine site] (higher affinity), L838417
[benzodiazepine site] (Partial agonist), Ro19-4603
[benzodiazepine site] (Inverse agonist), TP003
[benzodiazepine site] (Partial agonist), TPA023
[benzodiazepine site] (Partial agonist)
Labelled ligands [11C]flumazenil [benzodiazepine site] (Allosteric
modulator, Antagonist), [18F]fluoroethylflumazenil
[benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker),
[3H]CGS8216 [benzodiazepine site] (Allosteric
modulator, Mixed), [3H]flunitrazepam [benzodiazepine
site] (Allosteric modulator, Positive), [3H]gabazine
[GABA site] (Antagonist), [3H]muscimol [GABA site]
(Agonist), [3H]zolpidem [benzodiazepine site] (Allosteric
modulator, Positive)
[11C]flumazenil [benzodiazepine site] (Allosteric
modulator, Antagonist), [18F]fluoroethylflumazenil
[benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker),
[3H]CGS8216 [benzodiazepine site] (Allosteric
modulator, Mixed), [3H]flunitrazepam [benzodiazepine
site] (Allosteric modulator, Full agonist), [3H]gabazine
[GABA site] (Antagonist), [3H]muscimol [GABA site]
(Agonist)
[11C]flumazenil [benzodiazepine site] (Allosteric
modulator, Antagonist), [18F]fluoroethylflumazenil
[benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker),
[3H]CGS8216 [benzodiazepine site] (Allosteric
modulator, Mixed), [3H]flunitrazepam [benzodiazepine
site] (Allosteric modulator, Full agonist), [3H]gabazine
[GABA site] (Antagonist), [3H]muscimol [GABA site]
(Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes
potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a Æ
or γ subunit causes a modest, or pronounced, reduction
in inhibitory potency, respectively [191]
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Nomenclature GABAA receptor α4 subunit GABAA receptor α5 subunit GABAA receptor α6 subunit
HGNC, UniProt GABRA4, P48169 GABRA5, P31644 GABRA6, Q16445
Agonists gaboxadol [GABA site], isoguvacine [GABA site],
muscimol [GABA site], piperidine-4-sulphonic acid
[GABA site] (low efficacy)
gaboxadol [GABA site], isoguvacine [GABA site],
isonipecotic acid [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site],
muscimol [GABA site], piperidine-4-sulphonic acid
[GABA site] (low efficacy)
Selective agonists isonipecotic acid [GABA site] (relatively high efficacy) – isonipecotic acid [GABA site] (relatively high efficacy)
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric
modulators
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+
(Inhibition), tetrahydrodeoxycorticosterone
(Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+
(Inhibition), tetrahydrodeoxycorticosterone
(Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+
(Inhibition), tetrahydrodeoxycorticosterone
(Potentiation)
Allosteric modulators flumazenil (Partial agonist) flunitrazepam [benzodiazepine site] (Positive) (pKi 8.3)
[122], alprazolam [benzodiazepine site] (Positive)
(pEC50 8) [6], α3IA [benzodiazepine site] (Inverse
agonist), DMCM [benzodiazepine site] (Inverse
agonist), Ro15-4513 [benzodiazepine site] (Inverse
agonist), Ro19-4603 [benzodiazepine site] (Inverse
agonist), TP003 [benzodiazepine site] (Antagonist),
TPA023 [benzodiazepine site] (Antagonist), ZK93426
[benzodiazepine site] (Antagonist), bretazenil
[benzodiazepine site] (Full agonist), flumazenil
[benzodiazepine site] (Antagonist), ocinaplon
[benzodiazepine site] (Partial agonist)
bretazenil [benzodiazepine site] (Full agonist),
flumazenil [benzodiazepine site] (Partial agonist)
Selective allosteric
modulators
Ro15-4513 [benzodiazepine site] (Full agonist),
bretazenil [benzodiazepine site] (Full agonist)
α5IA [benzodiazepine site] (Inverse agonist), L655708
[benzodiazepine site] (Inverse agonist), L838417
[benzodiazepine site] (Partial agonist), MRK016
[benzodiazepine site] (Inverse agonist), RO4938581
[benzodiazepine site] (Inverse agonist), RY024
[benzodiazepine site] (Inverse agonist)
Ro15-4513 [benzodiazepine site] (Full agonist)
Labelled ligands [11C]flumazenil [benzodiazepine site] (Allosteric
modulator, Partial agonist), [18F]fluoroethylflumazenil
[benzodiazepine site] (Allosteric modulator,
Antagonist), [35S]TBPS [anion channel] (Channel
blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]Ro154513
[benzodiazepine site] (Allosteric modulator, Full
agonist), [3H]gabazine [GABA site] (Antagonist),
[3H]muscimol [GABA site] (Agonist)
[3H]RY80 [benzodiazepine site] (Selective Binding)
(pKd 9.2) [309] – Rat, [
11C]flumazenil [benzodiazepine
site] (Allosteric modulator, Antagonist),
[18F]fluoroethylflumazenil [benzodiazepine site]
(Allosteric modulator, Antagonist), [35S]TBPS [anion
channel] (Channel blocker), [3H]CGS8216
[benzodiazepine site] (Allosteric modulator, Mixed),
[3H]L655708 [benzodiazepine site] (Allosteric
modulator, Inverse agonist), [3H]flunitrazepam
[benzodiazepine site] (Allosteric modulator, Full
agonist), [3H]gabazine [GABA site] (Antagonist),
[3H]muscimol [GABA site] (Agonist)
[11C]flumazenil [benzodiazepine site] (Allosteric
modulator, Partial agonist), [18F]fluoroethylflumazenil
[benzodiazepine site] (Allosteric modulator,
Antagonist), [35S]TBPS [anion channel] (Channel
blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]Ro154513
[benzodiazepine site] (Allosteric modulator, Full
agonist), [3H]gabazine [GABA site] (Antagonist),
[3H]muscimol [GABA site] (Agonist)
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Nomenclature GABAA receptor α4 subunit GABAA receptor α5 subunit GABAA receptor α6 subunit
Comments diazepam and flunitrazepam are not active at this
subunit. Zn2+ is an endogenous allosteric regulator
and causes potent inhibition of receptors formed from
binary combinations of α and β subunits,
incorporation of a Æ or γ subunit causes a modest, or
pronounced, reduction in inhibitory potency,
respectively [191]. [3H]Ro154513 selectively labels
α4-subunit-containing receptors in the presence of a
saturating concentration of a ’classical’
benzodiazepine (e.g. diazepam)
Zn2+ is an endogenous allosteric regulator and causes
potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a Æ
or γ subunit causes a modest, or pronounced,
reduction in inhibitory potency, respectively [191]
diazepam and flunitrazepam are not active at this
subunit. Zn2+ is an endogenous allosteric regulator
and causes potent inhibition of receptors formed from
binary combinations of α and β subunits,
incorporation of a Æ or γ subunit causes a modest, or
pronounced, reduction in inhibitory potency,
respectively [191]. [3H]Ro154513 selectively labels
α6-subunit-containing receptors in the presence of a
saturating concentration of a ’classical’
benzodiazepine (e.g. diazepam)
Nomenclature GABAA receptor β1 subunit GABAA receptor β2 subunit GABAA receptor β3 subunit GABAA receptor γ1 subunit GABAA receptor γ2 subunit
HGNC, UniProt GABRB1, P18505 GABRB2, P47870 GABRB3, P28472 GABRG1, Q8N1C3 GABRG2, P18507
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Allosteric modulators – – etazolate (Binding) (pIC50
5.5) [378]
– –
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a Æ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [191]
Nomenclature GABAA receptor γ3 subunit GABAA receptor Æ subunit GABAA receptor  subunit GABAA receptor  subunit GABAA receptor  subunit
HGNC, UniProt GABRG3, Q99928 GABRD, O14764 GABRE, P78334 GABRQ, Q9UN88 GABRP, O00591
Selective agonists – gaboxadol [GABA site] – – –
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments Zn2+ is an endogenous allosteric
regulator and causes potent
inhibition of receptors formed
from binary combinations of α
and β subunits, incorporation of
a Æ or γ subunit causes a modest,
or pronounced, reduction in
inhibitory potency, respectively
[191]
Zn2+ is an endogenous allosteric
regulator and causes potent
inhibition of receptors formed
from binary combinations of α
and β subunits, incorporation of
a Æ or γ subunit causes a modest,
or pronounced, reduction in
inhibitory potency, respectively
– – –
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Nomenclature GABAA receptor 1 subunit GABAA receptor 2 subunit GABAA receptor 3 subunit
HGNC, UniProt GABRR1, P24046 GABRR2, P28476 GABRR3, A8MPY1
Agonists isoguvacine [GABA site] (Partial agonist), muscimol
[GABA site] (Partial agonist)
isoguvacine [GABA site] (Partial agonist), muscimol
[GABA site] (Partial agonist)
isoguvacine [GABA site] (Partial agonist), muscimol
[GABA site] (Partial agonist)
Selective agonists ()-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site] ()-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site] ()-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site]
Antagonists gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
Selective antagonists cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site],
TPMPA [GABA site], aza-THIP [GABA site]
cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site],
TPMPA [GABA site], aza-THIP [GABA site]
cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site],
TPMPA [GABA site], aza-THIP [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments bicuculline is not active at this subunit bicuculline is not active at this subunit bicuculline is not active at this subunit
Comments: The potency and efficacy of many GABA agonists
vary between GABAA receptor isoforms [104, 172, 192]. For ex-
ample, gaboxadol is a partial agonist at receptors with the sub-
unit composition α4β3γ2, but elicits currents in excess of those
evoked by GABA at the α4β3Æ receptor where GABA itself is a
low efficacy agonist [29, 38]. The antagonists bicuculline and
gabazine differ in their ability to suppress spontaneous openings
of the GABAA receptor, the former being more effective [333].
The presence of the γ subunit within the heterotrimeric com-
plex reduces the potency and efficacy of agonists [319]. The
GABAA receptor contains distinct allosteric sites that bind barbi-
turates and endogenous (e.g., 5α-pregnan-3α-ol-20-one) and syn-
thetic (e.g., alphaxalone) neuroactive steroids in a diastereo- or
enantio-selective manner [26, 131, 142, 341]. Picrotoxinin and
TBPS act at an allosteric site within the chloride channel pore
to negatively regulate channel activity; negative allosteric regula-
tion by γ-butyrolactone derivatives also involves the picrotoxinin
site, whereas positive allosteric regulation by such compounds
is proposed to occur at a distinct locus. Many intravenous
(e.g., etomidate, propofol) and inhalational (e.g., halothane,
isoflurane) anaesthetics and alcohols also exert a regulatory influ-
ence uponGABAA receptor activity [33, 262]. Specific amino acid
residues within GABAA receptor α- and β-subunits that influence
allosteric regulation by anaesthetic and non-anaesthetic com-
pounds have been identified [129, 142]. Photoaffinity labelling
of distinct amino acid residues within purified GABAA receptors
by the etomidate derivative, [3H]azietomidate, has also been
demonstrated [202] and this binding subject to positive allosteric
regulation by anaesthetic steroids [201]. An array of natural prod-
ucts including flavonoid and terpenoid compounds exert varied
actions at GABAA receptors (reviewed in detail in [165]).
In addition to the agents listed in the table, modulators of GABAA
receptor activity that exhibit subunit dependent activity include:
salicylidene salicylhydrazide [negative allosteric modulator selec-
tive for β1- versus β2-, or β3-subunit-containing receptors [334]];
fragrent dioxane derivatives [positive allosteric modulators selec-
tive for β1- versus β2-, or β3-subunit-containing receptors [302]];
loreclezole, etomidate, tracazolate, mefenamic acid, etifoxine,
stiripentol, valerenic acid amide [positive allosteric modulators
with selectivity for β2/β3- over β1-subunit-containing recep-
tors [99, 182, 190]]; tracazolate [intrinsic efficacy, i.e., poten-
tiation, or inhibition, is dependent upon the identity of the
γ1-3-, Æ-, or -subunit co-assembed with α1- and β1-subunits
[332]]; amiloride [selective blockade of receptors containing an
α6-subunit [98]]; furosemide [selective blockade of receptors con-
taining an α6-subunit co-assembled with β2/β3-, but not β1-
subunit [190]]; La3+ [potentiates responses mediated by α1β3γ2L
receptors, weakly inhibits α6β3γ2L receptors, and strongly blocks
α6β3Æ and α4β3Æ receptors [38, 295]]; ethanol [selectively poten-
tiates responses mediated by α4β3Æ and α6β3Æ receptors versus
receptors in which β2 replaces β3, or γ replaces Æ [351], but see
also [189]]; DS1 and DS2 [selectively potentiate responses medi-
ated by Æ-subunit-containing receptors [347]]. It should be noted
that the apparent selectivity of some positive allosteric modula-
tors (e.g., neurosteroids such as 5α-pregnan-3α-ol-20-one for Æ-
subunit-containing receptors (e.g., α1β3Æ) may be a consequence
of the unusually low efficacy of GABA at this receptor isoform
[25, 29].
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Glycine receptors
Ligand-gated ion channels! Glycine receptors
Overview: The inhibitory glycine receptor (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Glycine Re-
ceptors) is a member of the Cys-loop superfamily of transmitter-
gated ion channels that includes the zinc activated channels,
GABAA, nicotinic acetylcholine and 5-HT3 receptors [215]. The
receptor is expressed either as a homo-pentamer of α subunits,
or a complex now thought to harbour 2α and 3β subunits [28,
118], that contain an intrinsic anion channel. Four differentially
expressed isoforms of the α-subunit (α1-α4) and one variant of
the β-subunit (β1, GLRB, P48167) have been identified by ge-
nomic and cDNA cloning. Further diversity originates from al-
ternative splicing of the primary gene transcripts for α1 (α1INS
and α1del), α2 (α2A and α2B), α3 (α3S and α3L) and β (β17) sub-
units and by mRNA editing of the α2 and α3 subunit [91, 230,
261]. Both α2 splicing and α3 mRNA editing can produce sub-
units (i.e., α2B and α3P185L) with enhanced agonist sensitivity.
Predominantly, the mature form of the receptor contains α1 (or
α3) and β subunits while the immature form is mostly composed
of only α2 subunits. RNA transcripts encoding the α4-subunit
have not been detected in adult humans. The N-terminal domain
of the α-subunit contains both the agonist and strychnine bind-
ing sites that consist of several discontinuous regions of amino
acids. Inclusion of the β-subunit in the pentameric glycine recep-
tor contributes to agonist binding, reduces single channel con-
ductance and alters pharmacology. The β-subunit also anchors
the receptor, via an amphipathic sequence within the large in-
tracellular loop region, to gephyrin. The latter is a cytoskeletal
attachment protein that binds to a number of subsynaptic pro-
teins involved in cytoskeletal structure and thus clusters and an-
chors hetero-oligomeric receptors to the synapse [185, 188, 247].
G-protein βγ subunits enhance the open state probability of na-
tive and recombinant glycine receptors by association with do-
mains within the large intracellular loop [371, 372]. Intracellular
chloride concentration modulates the kinetics of native and re-
combinant glycine receptors [280]. Intracellular Ca2+ appears to
increase native and recombinant glycine receptor affinity, pro-
longing channel open events, by a mechanism that does not in-
volve phosphorylation [105].
Nomenclature glycine receptor α1 subunit glycine receptor α2 subunit
HGNC, UniProt GLRA1, P23415 GLRA2, P23416
Selective agonists
(potency order)
glycine > β-alanine > taurine glycine > β-alanine > taurine
Functional
Characteristics
γ = 86 pS (main state); (+ β = 44 pS) γ = 111 pS (main state); (+ β = 54 pS)
Selective antagonists ginkgolide X (pIC50 6.1), pregnenolone sulphate (pKi 5.7), nifedipine (pIC50 5.5),
bilobalide (pIC50 4.7), tropisetron (pKi 4.1), colchicine (pIC50 3.5), HU-308 (weak
inhibition), PMBA, strychnine
HU-210 (pIC50 7), WIN55212-2 (pIC50 6.7), HU-308 (pIC50 6), ginkgolide X (pIC50
5.6), pregnenolone sulphate (pKi 5.3), bilobalide (pIC50 5.1), tropisetron (pKi 4.9),
colchicine (pIC50 4.2), 5,7-dichlorokynurenic acid (pIC50 3.7), PMBA, strychnine
Channel blockers ginkgolide B (pIC50 5.1–6.2), cyanotriphenylborate (pIC50 5.9) [292], picrotin (pIC50
5.3), picrotoxinin (pIC50 5.3), picrotoxin (pIC50 5.2)
picrotoxinin (pIC50 6.4), picrotoxin (pIC50 5.6), ginkgolide B (pIC50 4.9–5.4),
picrotin (pIC50 4.9), cyanotriphenylborate (pIC50 >4.7) [292]
Endogenous
allosteric modulators
Zn2+ (Potentiation) (pEC50 7.4), Cu2+ (Inhibition) (pIC50 4.8–5.4), Zn2+ (Inhibition)
(pIC50 4.8), Extracellular H+ (Inhibition)
Zn2+ (Potentiation) (pEC50 6.3), Cu2+ (Inhibition) (pIC50 4.8), Zn2+ (Inhibition)
(pIC50 3.4)
Selective allosteric
modulators
anandamide (Potentiation) (pEC50 7.4), HU-210 (Potentiation) (pEC50 6.6),
1
9-tetrahydrocannabinol (Potentiation) (pEC50 5.5)
1
9-tetrahydrocannabinol (Potentiation) (pEC50 6)
Labelled ligands [3H]strychnine (Antagonist) [3H]strychnine (Antagonist)
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Nomenclature glycine receptor α3 subunit
glycine receptor α4 subunit
(pseudogene in humans) glycine receptor β subunit
HGNC, UniProt GLRA3, O75311 GLRA4, Q5JXX5 GLRB, P48167
Selective agonists
(potency order)
glycine > β-alanine > taurine – –
Functional Characteristics γ = 105 pS (main state); (+ β = 48) – –
Selective antagonists HU-210 (pIC50 7.3), HU-308 (pIC50 7), WIN55212-2 (pIC50
7), (12E,20Z,18S)-8-hydroxyvariabilin (pIC50 5.2),
nifedipine (pIC50 4.5), strychnine
– nifedipine (when co-expressed with the α1 subunit) (pIC50 5.9),
pregnenolone sulphate (when co-expressed with the α1 subunit) (pKi 5.6),
tropisetron (when co-expressed with the α2 subunit) (pKi 5.3),
pregnenolone sulphate (when co-expressed with the α2 subunit) (pKi 5),
nifedipine (when co-expressed with the α3 subunit) (pIC50 4.9), bilobalide
(when co-expressed with the α2 subunit) (pIC50 4.3), bilobalide (when
co-expressed with the α1 subunit) (pIC50 3.7), ginkgolide X (when
co-expressed with the α1 subunit) (pIC50 >3.5), ginkgolide X (when
co-expressed with the α2 subunit) (pIC50 >3.5)
Channel blockers picrotoxinin (pIC50 6.4), ginkgolide B (pIC50 5.7), picrotin
(pIC50 5.2), picrotoxin (block is weaker when β subunit is
co-expressed)
– ginkgolide B (when co-expressed with the α2 subunit) (pIC50 6.1–6.9),
ginkgolide B (when co-expressed with the α1 subunit) (pIC50 5.6–6.7),
ginkgolide B (when co-expressed with the α3 subunit) (pIC50 6.3),
cyanotriphenylborate (when co-expressed with the human α1 subunit)
(pIC50 5.6) [292] – Rat, cyanotriphenylborate (when co-expressed with the
human α2 subunit) (pIC50 5.1) [292] – Rat, picrotoxinin (when co-expressed
with the α3 subunit) (pIC50 5.1), picrotin (when co-expressed with the α1
subunit) (pIC50 4.6), picrotin (when co-expressed with the α3 subunit)
(pIC50 4.6), picrotoxinin (when co-expressed with the α1 subunit) (pIC50
4.6), picrotoxin (when co-expressed with the α2 subunit) (pIC50 4.5),
picrotoxin (when co-expressed with the α1 subunit) (pIC50 3.7)
Endogenous allosteric
modulators
Cu2+ (Inhibition) (pIC50 5), Zn2+ (Inhibition) (pIC50 3.8) – Zn2+ (Inhibition) (pIC50 4.9), Zn2+ (Inhibition) (pIC50 3.7)
Selective allosteric
modulators
1
9-tetrahydrocannabinol (Potentiation) (pEC50 5.3) – –
Labelled ligands [3H]strychnine (Antagonist) – –
Comments – – Ligand interaction data for hetero-oligomer receptors containing the β
subunit are also listed under the α subunit
Comments: Data in the table refer to homo-oligomeric assem-
blies of the α-subunit, significant changes introduced by co-
expression of the β1 subunit are indicated in parenthesis. Not
all glycine receptor ligands are listed within the table, but some
that may be useful in distinguishing between glycine receptor
isoforms are indicated (see detailed view pages for each subunit:
α1, α2, α3, α4, β ). Pregnenolone sulphate, tropisetron and
colchicine, for example, although not selective antagonists of
glycine receptors, are included for this purpose. Strychnine is a
potent and selective competitive glycine receptor antagonist with
affinities in the range 5-15 nM. RU5135 demonstrates compara-
ble potency, but additionally blocks GABAA receptors. There are
conflicting reports concerning the ability of cannabinoids to in-
hibit [210], or potentiate and at high concentrations activate [4,
73, 128, 363, 368] glycine receptors. Nonetheless, cannabinoid
analogues may hold promise in distinguishing between glycine
receptor subtypes [368]. In addition, potentiation of glycine re-
ceptor activity by cannabinoids has been claimed to contribute
to cannabis-induced analgesia relying on Ser296/307 (α1/α3) in
M3 [363]. Several analogues of muscimol and piperidine act as
agonists and antagonists of both glycine and GABAA receptors.
Picrotoxin acts as an allosteric inhibitor that appears to bind
within the pore, and shows strong selectivity towards homomeric
receptors. While its components, picrotoxinin and picrotin, have
equal potencies at α1 receptors, their potencies at α2 and α3 re-
ceptors differ modestly and may allow some distinction between
different receptor types [369]. Binding of picrotoxin within the
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pore has been demonstrated in the crystal structure of the related
C. elegansGluCl Cys-loop receptor [132]. In addition to the com-
pounds listed in the table, numerous agents act as allosteric reg-
ulators of glycine receptors (comprehensively reviewed in [197,
216, 354, 373]). Zn2+ acts through distinct binding sites of
high- and low-affinity to allosterically enhance channel func-
tion at low (<10 M) concentrations and inhibits responses at
higher concentrations in a subunit selective manner [237]. The
effect of Zn2+ is somewhat mimicked by Ni2+. Endogenous
Zn2+ is essential for normal glycinergic neurotransmission me-
diated by α1 subunit-containing receptors [135]. Elevation of in-
tracellular Ca2+ produces fast potentiation of glycine receptor-
mediated responses. Dideoxyforskolin (4 M) and tamoxifen
(0.2-5 M) both potentiate responses to low glycine concentra-
tions (15 M), but act as inhibitors at higher glycine concen-
trations (100 M). Additional modulatory agents that enhance
glycine receptor function include inhalational, and several in-
travenous general anaesthetics (e.g. minaxolone, propofol and
pentobarbitone) and certain neurosteroids. Ethanol and higher
order n-alcohols also enhance glycine receptor function although
whether this occurs by a direct allosteric action at the recep-
tor [225], or through βγ subunits [370] is debated. Recent crys-
tal structures of the bacterial homologue, GLIC, have identified
transmembrane binding pockets for both anaesthetics [259] and
alcohols [144]. Solvents inhaled as drugs of abuse (e.g. toluene,
1-1-1-trichloroethane) may act at sites that overlap with those
recognising alcohols and volatile anaesthetics to produce poten-
tiation of glycine receptor function. The function of glycine re-
ceptors formed as homomeric complexes of α1 or α2 subunits,
or hetero-oligomers of α1/β or α2/β subunits, is differentially af-
fected by the 5-HT3 receptor antagonist tropisetron (ICS 205-
930) which may evoke potentiation (whichmay occur within the
femtomolar range at the homomeric glycine α1 receptor), or inhi-
bition, depending upon the subunit composition of the receptor
and the concentrations of the modulator and glycine employed.
Potentiation and inhibition by tropeines involves different bind-
ing modes [220]. Additional tropeines, including atropine, mod-
ulate glycine receptor activity.
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Ionotropic glutamate receptors
Ligand-gated ion channels! Ionotropic glutamate receptors
Overview: The ionotropic glutamate receptors comprise mem-
bers of the NMDA (N-methyl-D-aspartate), AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazoleproprionic acid) and kainate re-
ceptor classes, named originally according to their preferred, syn-
thetic, agonist [76, 208, 338]. Receptor heterogeneity within each
class arises from the homo-oligomeric, or hetero-oligomeric, as-
sembly of distinct subunits into cation-selective tetramers. Each
subunit of the tetrameric complex comprises an extracellular
amino terminal domain (ATD), an extracellular ligand binding
domain (LBD), three transmembrane domains composed of three
membrane spans (M1, M3 and M4), a channel lining re-entrant
‘p-loop’ (M2) located between M1 and M3 and an intracellular
carboxy- terminal domain (CTD) [168, 193, 226, 250, 338]. The
X-ray structure of a homomeric ionotropic glutamate receptor
(GluA2 - see below) has recently been solved at 3.6Å resolution
[313] and although providing themost complete structural infor-
mation current available may not representative of the subunit
arrangement of, for example, the heteromeric NMDA receptors
[171]. It is beyond the scope of this supplement to discuss the
pharmacology of individual ionotropic glutamate receptor iso-
forms in detail; such information can be gleaned from [55, 65, 76,
93, 155, 156, 179, 265, 266, 267, 338, 362]. Agents that discrim-
inate between subunit isoforms are, where appropriate, noted in
the tables and additional compounds that distinguish between
receptor isoforms are indicated in the text below.
The classification of glutamate receptor subunits has re-
cently been re-addressed by NC-IUPHAR [62]. The scheme
developed recommends a revised nomenclature for ionotropic
glutamate receptor subunits that is adopted here.
NMDA receptors
NMDA receptors assemble as obligate heteromers that may
be drawn from GluN1, GluN2A, GluN2B, GluN2C, GluN2D,
GluN3A and GluN3B subunits. Alternative splicing can gener-
ate eight isoforms of GluN1 with differing pharmacological prop-
erties. Various splice variants of GluN2B, 2C, 2D and GluN3A
have also been reported. Activation of NMDA receptors con-
taining GluN1 and GluN2 subunits requires the binding of two
agonists, glutamate to the S1 and S2 regions of the GluN2 sub-
unit and glycine to S1 and S2 regions of the GluN1 subunit [56,
92]. The minimal requirement for efficient functional expres-
sion of NMDA receptors in vitro is a di-heteromeric assembly of
GluN1 and at least one GluN2 subunit variant, as a dimer of het-
erodimers arrangement in the extracellular domain [106, 171,
226]. However, more complex tri-heteromeric assemblies, incor-
porating multiple subtypes of GluN2 subunit, or GluN3 subunits,
can be generatedin vitro and occurin vivo. The NMDA receptor
channel commonly has a high relative permeability to Ca2+ and
is blocked, in a voltage-dependent manner, by Mg2+ such that at
resting potentials the response is substantially inhibited.
AMPA and Kainate receptors
AMPA receptors assemble as homomers, or heteromers, that may
be drawn from GluA1, GluA2, GluA3 and GluA4 subunits. Trans-
membrane AMPA receptor regulatory proteins (TARPs) of class I
(i.e. γ2, γ3, γ4 and γ8) act, with variable stoichiometry, as auxil-
iary subunits to AMPA receptors and influence their trafficking,
single channel conductance gating and pharmacology (reviewed
in [95, 152, 239, 336]). Functional kainate receptors can be ex-
pressed as homomers of GluK1, GluK2 or GluK3 subunits. GluK1-
3 subunits are also capable of assembling into heterotetramers
(e.g. GluK1/K2; [199, 276, 279]). Two additional kainate recep-
tor subunits, GluK4 and GluK5, when expressed individually,
form high affinity binding sites for kainate, but lack function,
but can form heteromers when expressed with GluK1-3 subunits
(e.g. GluK2/K5; reviewed in [156, 276, 279]). Kainate receptors
may also exhibit ‘metabotropic’ functions [199, 288]. As found
for AMPA receptors, kainate receptors are modulated by auxil-
iary subunits (Neto proteins, [200, 276]). An important function
difference between AMPA and kainate receptors is that the latter
require extracellular Na+ and Cl- for their activation [35, 282].
RNA encoding the GluA2 subunit undergoes extensive RNA edit-
ing in which the codon encoding a p-loop glutamine residue (Q)
is converted to one encoding arginine (R). This Q/R site strongly
influences the biophysical properties of the receptor. Recombi-
nant AMPA receptors lacking RNA edited GluA2 subunits are: (1)
permeable to Ca2+; (2) blocked by intracellular polyamines at de-
polarized potentials causing inward rectification (the latter being
reduced by TARPs); (3) blocked by extracellular argiotoxin and
Joro spider toxins and (4) demonstrate higher channel conduc-
tances than receptors containing the edited form of GluA2 [150,
300]. GluK1 and GluK2, but not other kainate receptor subunits,
are similarly edited and broadly similar functional characteristics
apply to kainate receptors lacking either an RNA edited GluK1,
or GluK2, subunit [199, 276]. Native AMPA and kainate recep-
tors displaying differential channel conductances, Ca2+ perme-
abilites and sensitivity to block by intracellular polyamines have
been identified [64, 150, 206]. GluA1-4 can exist as two variants
generated by alternative splicing (termed ‘flip’ and ‘flop’) that
differ in their desensitization kinetics and their desensitization
in the presence of cyclothiazide which stabilises the nondesensi-
tized state. TARPs also stabilise the non-desensitized conforma-
tion of AMPA receptors and facilitate the action of cyclothiazide
[239]. Splice variants of GluK1-3 also exist which affects their
trafficking [199, 276].
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Nomenclature GluA1 GluA2 GluA3 GluA4
HGNC, UniProt GRIA1, P42261 GRIA2, P42262 GRIA3, P42263 GRIA4, P48058
Agonists (S)-5-fluorowillardiine, AMPA (S)-5-fluorowillardiine, AMPA (S)-5-fluorowillardiine, AMPA (S)-5-fluorowillardiine, AMPA
Selective antagonists ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
Channel blockers extracellular argiotoxin, extracellular
joro toxin (selective for channels
lacking GluA2)
extracellular argiotoxin extracellular argiotoxin, extracellular
joro toxin (selective for channels
lacking GluA2)
extracellular argiotoxin, extracellular
joro toxin (selective for channels lacking
GluA2)
Allosteric modulators LY392098 (Positive) (pEC50 5.8) [240], LY404187 (Positive) (pEC50 5.2) [240], cyclothiazide (Positive) (pEC50 4.7) [240], CX516 (Positive), CX546 (Positive), IDRA-21 (Positive),
LY503430 (Positive), S18986 (Positive), aniracetam (Positive), piracetam (Positive)
Labelled ligands [3H]AMPA (Agonist), [3H]CNQX
(Antagonist)
[3H]AMPA (Agonist), [3H]CNQX
(Antagonist)
[3H]AMPA, [3H]CNQX [3H]AMPA (Agonist), [3H]CNQX
Comments piracetam and aniracetam are examples of pyrrolidinones. cyclothiazide, S18986, and IDRA-21 are examples of benzothiadiazides. CX516 and CX546 are examples of
benzylpiperidines. LY392098, LY404187 and LY503430 are examples of biarylpropylsulfonamides. Also blocked by intracellular polyamines.
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Nomenclature GluD1 GluD2 GluK1 GluK2 GluK3 GluK4 GluK5
HGNC, UniProt GRID1, Q9ULK0 GRID2, O43424 GRIK1, P39086 GRIK2, Q13002 GRIK3, Q13003 GRIK4, Q16099 GRIK5, Q16478
Agonists – – (S)-4-AHCP,
(S)-5-iodowillardiine,
8-deoxy-
neodysiherbaine ,
ATPA, LY339434,
SYM2081, domoic acid,
dysiherbaine,
kainate
SYM2081, domoic acid,
dysiherbaine,
kainate
SYM2081,
dysiherbaine, kainate
(low potency)
SYM2081, domoic acid,
dysiherbaine,
kainate
SYM2081, domoic acid,
dysiherbaine,
kainate
Selective antagonists – –
2,4-epi-
neodysiherbaine ,
ACET, LY382884,
LY466195, MSVIII-19,
NS3763
(non-competitive),
UBP302, UBP310
2,4-epi-
neodysiherbaine – – –
Allosteric modulators – – concanavalin A (Positive) concanavalin A (Positive) – – –
Labelled ligands – – [3H]UBP310 (Antagonist)
(pKd 7.7) [13],
[3H](2S,4R)-4-
methylglutamate
(Agonist), [3H]kainate
(Agonist)
[3H](2S,4R)-4-
methylglutamate
(Agonist), [3H]kainate
(Agonist)
[3H]UBP310
(Antagonist) (pKd 6.3)
[13],
[3H](2S,4R)-4-
methylglutamate
(Agonist), [3H]kainate
(Agonist)
[3H](2S,4R)-4-
methylglutamate
(Agonist), [3H]kainate
(Agonist)
[3H](2S,4R)-4-
methylglutamate
(Agonist), [3H]kainate
(Agonist)
Comments – – – Intracellular polyamines
are subtype selective
channel blockers (GluK3
 GluK2)
domoic acid and
concanavalin A are
inactive at the GluK3
subunit. Intracellular
polyamines are subtype
selective channel
blockers (GluK3
GluK2)
– –
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Nomenclature GluN1 GluN2A GluN2B GluN2C GluN2D
HGNC, UniProt GRIN1, Q05586 GRIN2A, Q12879 GRIN2B, Q13224 GRIN2C, Q14957 GRIN2D, O15399
Endogenous
agonists
D-aspartic acid [glutamate
site], D-serine [glycine site],
L-aspartic acid [glutamate site],
glycine [glycine site]
D-aspartic acid [glutamate site]
(GluN2D > GluN2C = GluN2B
> GluN2A), D-serine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A),
L-aspartic acid [glutamate site]
(GluN2D = GluN2B > GluN2C
= GluN2A), glycine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A)
D-aspartic acid [glutamate site]
(GluN2D > GluN2C = GluN2B
> GluN2A), D-serine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A),
L-aspartic acid [glutamate site]
(GluN2D = GluN2B > GluN2C
= GluN2A), glycine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A)
D-aspartic acid [glutamate site]
(GluN2D > GluN2C = GluN2B
> GluN2A), D-serine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A),
L-aspartic acid [glutamate site]
(GluN2D = GluN2B > GluN2C
= GluN2A), glycine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A)
D-aspartic acid [glutamate site]
(GluN2D > GluN2C = GluN2B
> GluN2A), D-serine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A),
L-aspartic acid [glutamate site]
(GluN2D = GluN2B > GluN2C
= GluN2A), glycine [glycine
site] (GluN2D > GluN2C >
GluN2B > GluN2A)
Agonists (+)-HA966 [glycine site] (Partial
agonist),
(RS)-(tetrazol-5-yl)glycine
[glutamate site], NMDA
[glutamate site],
homoquinolinic acid
[glutamate site] (Partial
agonist)
(+)-HA966 [glycine site] (Partial
agonist),
(RS)-(tetrazol-5-yl)glycine
[glutamate site] (GluN2D >
GluN2C = GluN2B > GluN2A),
NMDA [glutamate site]
(GluN2D > GluN2C > GluN2B
> GluN2A),
homoquinolinic acid [glutamate
site] (GluN2B  GluN2A 
GluN2D > GluN2C; partial
agonist at GluN2A and
GluN2C)
(+)-HA966 [glycine site] (Partial
agonist),
(RS)-(tetrazol-5-yl)glycine
[glutamate site] (GluN2D >
GluN2C = GluN2B > GluN2A),
NMDA [glutamate site]
(GluN2D > GluN2C > GluN2B
> GluN2A),
homoquinolinic acid [glutamate
site] (GluN2B  GluN2A 
GluN2D > GluN2C; partial
agonist at GluN2A and
GluN2C)
(RS)-(tetrazol-5-yl)glycine
[glutamate site] (GluN2D >
GluN2C = GluN2B > GluN2A),
NMDA [glutamate site]
(GluN2D > GluN2C > GluN2B
> GluN2A),
homoquinolinic acid [glutamate
site] (GluN2B  GluN2A 
GluN2D > GluN2C; partial
agonist at GluN2A and
GluN2C)
(RS)-(tetrazol-5-yl)glycine
[glutamate site] (GluN2D >
GluN2C = GluN2B > GluN2A),
NMDA [glutamate site]
(GluN2D > GluN2C > GluN2B
> GluN2A),
homoquinolinic acid [glutamate
site] (GluN2B  GluN2A 
GluN2D > GluN2C; partial
agonist at GluN2A and
GluN2C)
Selective
antagonists
5,7-dichlorokynurenic acid
[glycine site], GV196771A
[glycine site], L689560 [glycine
site], L701324 [glycine site]
5,7-dichlorokynurenic acid
[glycine site], CGP37849
[glutamate site], GV196771A
[glycine site], L689560 [glycine
site], L701324 [glycine site],
LY233053 [glutamate site],
NVP-AAM077 [glutamate site]
(GluN2A > GluN2B (human),
but weakly selective for rat
GluN2A versus GluN2B) [14,
97, 103, 252], UBP141
[glutamate site] (GluN2D 
GluN2C > GluN2A  GluN2B)
[245], conantokin-G [glutamate
site] (GluN2B > GluN2D =
GluN2C = GluN2A), d-AP5
[glutamate site], d-CCPene
[glutamate site] (GluN2A =
GluN2B > GluN2C = GluN2D),
selfotel [glutamate site]
5,7-dichlorokynurenic acid
[glycine site], CGP37849
[glutamate site], GV196771A
[glycine site], L689560 [glycine
site], L701324 [glycine site],
LY233053 [glutamate site],
NVP-AAM077 [glutamate site]
(GluN2A > GluN2B (human),
but weakly selective for rat
GluN2A versus GluN2B) [14,
97, 103, 252], UBP141
[glutamate site] (GluN2D 
GluN2C > GluN2A  GluN2B)
[245], conantokin-G [glutamate
site] (GluN2B > GluN2D =
GluN2C = GluN2A), d-AP5
[glutamate site], d-CCPene
[glutamate site] (GluN2A =
GluN2B > GluN2C = GluN2D),
selfotel [glutamate site]
5,7-dichlorokynurenic acid
[glycine site], CGP37849
[glutamate site], GV196771A
[glycine site], L689560 [glycine
site], L701324 [glycine site],
LY233053 [glutamate site],
UBP141 [glutamate site]
(GluN2D  GluN2C > GluN2A
 GluN2B) [245], conantokin-G
[glutamate site] (GluN2B >
GluN2D = GluN2C = GluN2A),
d-AP5 [glutamate site],
d-CCPene [glutamate site]
(GluN2A = GluN2B > GluN2C
= GluN2D), selfotel [glutamate
site]
5,7-dichlorokynurenic acid
[glycine site], CGP37849
[glutamate site], GV196771A
[glycine site], L689560 [glycine
site], L701324 [glycine site],
LY233053 [glutamate site],
UBP141 [glutamate site]
(GluN2D  GluN2C > GluN2A
 GluN2B) [245], conantokin-G
[glutamate site] (GluN2B >
GluN2D = GluN2C = GluN2A),
d-AP5 [glutamate site],
d-CCPene [glutamate site]
(GluN2A = GluN2B > GluN2C
= GluN2D), selfotel [glutamate
site]
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(continued)
Nomenclature GluN1 GluN2A GluN2B GluN2C GluN2D
Channel
blockers
– Mg2+ (GluN2A = GluN2B >
GluN2C = GluN2D),
N1-dansyl-spermine (GluN2A
= GluN2B GluN2C =
GluN2D), amantidine
(GluN2C = GluN2D  GluN2B
 GluN2A), dizocilpine,
ketamine, phencyclidine
Mg2+ (GluN2A = GluN2B >
GluN2C = GluN2D),
N1-dansyl-spermine (GluN2A
= GluN2B GluN2C =
GluN2D), amantidine
(GluN2C = GluN2D  GluN2B
 GluN2A), dizocilpine,
ketamine, phencyclidine
Mg2+ (GluN2A = GluN2B >
GluN2C = GluN2D),
N1-dansyl-spermine (GluN2A
= GluN2B GluN2C =
GluN2D), amantidine
(GluN2C = GluN2D  GluN2B
 GluN2A), dizocilpine,
ketamine, phencyclidine
Mg2+ (GluN2A = GluN2B >
GluN2C = GluN2D),
N1-dansyl-spermine (GluN2A
= GluN2B GluN2C =
GluN2D), amantidine
(GluN2C = GluN2D  GluN2B
 GluN2A), dizocilpine,
ketamine, phencyclidine
Labelled
ligands
[3H]CGP39653 [glutamate
site] (Selective Antagonist),
[3H]CGP61594 [glycine site]
(Antagonist), [3H]CGS19755
[glutamate site] (Antagonist),
[3H]CPP [glutamate site]
(Selective Antagonist),
[3H]L689560 [glycine site]
(Antagonist),
[3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine
[cation channel] (Antagonist),
[3H]glycine [glycine site]
(Agonist)
[3H]CGP39653 [glutamate
site] (Antagonist),
[3H]CGP61594 [glycine site]
(Antagonist), [3H]CGS19755
[glutamate site] (Antagonist),
[3H]CPP [glutamate site]
(Antagonist), [3H]L689560
[glycine site] (Antagonist),
[3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine
[cation channel] (Channel
blocker), [3H]glycine [glycine
site] (Agonist)
[3H]CGP39653 [glutamate
site] (Antagonist),
[3H]CGP61594 [glycine site]
(Antagonist), [3H]CGS19755
[glutamate site] (Antagonist),
[3H]CPP [glutamate site]
(Antagonist), [3H]L689560
[glycine site] (Antagonist),
[3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine
[cation channel] (Channel
blocker), [3H]glycine [glycine
site] (Agonist)
[3H]CGP39653 [glutamate
site] (Antagonist),
[3H]CGP61594 [glycine site]
(Antagonist), [3H]CGS19755
[glutamate site] (Antagonist),
[3H]CPP [glutamate site]
(Antagonist), [3H]L689560
[glycine site] (Antagonist),
[3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine
[cation channel] (Channel
blocker), [3H]glycine [glycine
site] (Agonist)
[3H]CGP39653 [glutamate
site] (Antagonist),
[3H]CGP61594 [glycine site]
(Antagonist), [3H]CGS19755
[glutamate site] (Antagonist),
[3H]CPP [glutamate site]
(Antagonist), [3H]L689560
[glycine site] (Selective
Antagonist), [3H]MDL105519
[glycine site] (Antagonist),
[3H]dizocilpine [cation
channel] (Channel blocker),
[3H]glycine [glycine site]
(Agonist)
Nomenclature GluN3A GluN3B
HGNC, UniProt GRIN3A, Q8TCU5 GRIN3B, O60391
Comments See the main comments section below for information on the pharmacology of GluN3A and GluN3B subunits
Comments: NMDA receptors
Potency orders unreferenced in the table are from [55, 84, 93, 194,
267, 338]. In addition to the glutamate and glycine binding sites
documented in the table, physiologically important inhibitorymodu-
latory sites exist forMg2+, Zn2+, and protons [65, 76, 338]. Voltage-
independent inhibition by Zn2+ binding with high affinity within the
ATD is highly subunit selective (GluN2A GluN2B > GluN2C 
GluN2D; [267, 338]). The receptor is also allosterically modulated,
in both positive and negative directions, by endogenous neuroactive
steroids in a subunit dependent manner [141, 221]. Tonic proton
blockade of NMDA receptor function is alleviated by polyamines and
the inclusion of exon 5 within GluN1 subunit splice variants, whereas
the non-competitive antagonists ifenprodil and traxoprodil increase
the fraction of receptors blocked by protons at ambient concentra-
tion. Inclusion of exon 5 also abolishes potentiation by polyamines
and inhibition by Zn2+ that occurs through binding in the ATD
[337]. Ifenprodil, traxoprodil, haloperidol, felbamate and Ro 8-4304
discriminate between recombinantNMDA receptors assembled from
GluN1 and either GluN2A, or GluN2B, subunits by acting as selec-
tive, non-competitive, antagonists of heterooligomers incorporating
GluN2B through a binding site at the ATD GluN1/GluN2B subunit in-
terface [171]. LY233536 is a competitive antagonist that also displays
selectivity for GluN2B over GluN2A subunit-containing receptors.
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Similarly, CGP61594 is a photoaffinity label that interacts selectively
with receptors incorporating GluN2B versus GluN2A, GluN2D and,
to a lesser extent, GluN2C subunits. TCN 201 and TCN 213 have
recently been shown to block GluN2A NMDA receptors selectively
by a mechanism that involves allosteric inhibition of glycine bind-
ing to the GluN1 site [27, 89, 125, 229]. In addition to influencing
the pharmacological profile of the NMDA receptor, the identity of
the GluN2 subunit co-assembled with GluN1 is an important deter-
minant of biophysical properties that include sensitivity to block by
Mg2+, single-channel conductance and maximal open probablity
and channel deactivation time [65, 92, 112]. Incorporation of the
GluN3A subunit into tri-heteromers containing GluN1 and GluN2
subunits is associated with decreased single-channel conductance,
reduced permeability to Ca2+ and decreased susceptibility to block
by Mg2+ [46, 130]. Reduced permeability to Ca2+ has also been
observed following the inclusion of GluN3B in tri-heteromers. The
expression of GluN3A, or GluN3B, with GluN1 alone forms, in Xeno-
pus laevis oocytes, a cation channel with unique properties that in-
clude activation by glycine (but not NMDA), lack of permeation by
Ca2+ and resistance to blockade by Mg2+ and NMDA receptor an-
tagonists [50]. The function of heteromers composed of GluN1 and
GluN3A is enhanced by Zn2+, or glycine site antagonists, binding
to the GluN1 subunit [218]. Zn2+ also directly activates such com-
plexes. The co-expression of GluN1, GluN3A and GluN3B appears
to be required to form glycine-activated receptors in mammalian cell
hosts [312].
AMPA and Kainate receptors
All AMPA receptors are additionally activated by kainate (and
domoic acid) with relatively low potency, (EC50 100 M). Inclu-
sion of TARPs within the receptor complex increases the potency and
maximal effect of kainate [152, 239]. AMPA is weak partial agonist at
GluK1 and at heteromeric assemblies of GluK1/GluK2, GluK1/GluK5
and GluK2/GluK5 [156]. Quinoxalinediones such as CNQX and
NBQX show limited selectivity between AMPA and kainate recep-
tors. Tezampanel also has kainate (GluK1) receptor activity as has
GYKI53655 (GluK3 and GluK2/GluK3) [156]. ATPO is a potent com-
petitive antagonist of AMPA receptors, has a weaker antagonist ac-
tion at kainate receptors comprising GluK1 subunits, but is devoid
of activity at kainate receptors formed from GluK2 or GluK2/GluK5
subunits. The pharmacological activity of ATPO resides with the (S)-
enantiomer. ACET and UBP310 may block GluK3, in addition to
GluK1 [13, 275]. (2S,4R)-4-methylglutamate (SYM2081) is equipo-
tent in activating (and desensitising) GluK1 and GluK2 receptor iso-
forms and, via the induction of desensitisation at low concentrations,
has been used as a functional antagonist of kainate receptors. Both
(2S,4R)-4-methylglutamate and LY339434 have agonist activity at
NMDA receptors. (2S,4R)-4-methylglutamate is also an inhibitor of
the glutamate transporters EAAT1 and EAAT2.
Delta subunits
GluD1 and GluD2 comprise, on the basis of sequence homology, an
‘orphan’ class of ionotropic glutamate receptor subunit. They do not
form a functional receptor when expressed solely, or in combination
with other ionotropic glutamate receptor subunits, in transfected
cells [377]. However, GluD2 subunits bind D-serine and glycine and
GluD2 subunits carrying the mutation A654T form a spontaneously
open channel that is closed by D-serine [251].
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IP3 receptor
Ligand-gated ion channels! IP3 receptor
Overview: The inositol 1,4,5-trisphosphate receptors (IP3R) are ligand-gated Ca
2+-release channels on intracellular Ca2+ store sites (such as the endoplasmic reticulum). They are responsible for the mobilization
of intracellular Ca2+ stores and play an important role in intracellular Ca2+ signalling in a wide variety of cell types. Three different gene products (types I-III) have been isolated, which assemble as large tetrameric
structures. IP3Rs are closely associated with certain proteins: calmodulin ( CALM1 CALM2 CALM3, P62158) and FKBP (and calcineurin via FKBP). They are phosphorylated by PKA, PKC, PKG and CaMKII.
Nomenclature IP3R1 IP3R2 IP3R3
HGNC, UniProt ITPR1, Q14643 ITPR2, Q14571 ITPR3, Q14573
Functional
Characteristics
Ca2+: (PBa/PK 6) single-channel conductance
70 pS (50 mM Ca2+)
Ca2+: single-channel conductance
70 pS (50 mM Ca2+)
390 pS (220 mM Cs+)
Ca2+: single-channel conductance
88 pS (55 mM Ba2+)
Endogenous
activators
cytosolic ATP (< mM range), cytosolic Ca2+
Concentration range: <7.510 4M, IP3 (endogenous;
nM - M range)
cytosolic Ca2+ (nM range), IP3 (endogenous; nM - M
range)
cytosolic Ca2+ (nM range), IP3 (endogenous; nM - M
range)
Activators adenophostin A (pharmacological; nM range),
inositol 2,4,5-trisphosphate (pharmacological; also
activated by other InsP3 analogues)
adenophostin A (pharmacological; nM range),
inositol 2,4,5-trisphosphate (pharmacological; also
activated by other InsP3 analogues)
–
Antagonists PIP2 (M range), caffeine (mM range), decavanadate
(M range), xestospongin C (M range)
decavanadate (M range) decavanadate (M range)
Comments IP3 R1 is also antagonised by calmodulin at high
cytosolic Ca2+ concentrations
– –
Comments: The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect.
Further Reading
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Nicotinic acetylcholine receptors
Ligand-gated ion channels! Nicotinic acetylcholine receptors
Overview: Nicotinic acetylcholine receptors are members of the
Cys-loop family of transmitter-gated ion channels that includes the
GABAA, strychnine-sensitive glycine and 5-HT3 receptors [7, 236,
308, 324, 361]. All nicotinic receptors are pentamers in which each
of the five subunits contains four α-helical transmembrane domains.
Genes encoding a total of 17 subunits (α1-10, β1-4, γ, Æ and )
have been identified [169]. All subunits with the exception of α8
(present in avian species) have been identified in mammals. All
α subunits possess two tandem cysteine residues near to the site
involved in acetylcholine binding, and subunits not named α lack
these residues [236]. The orthosteric ligand binding site is formed
by residues within at least three peptide domains on the α subunit
(principal component), and three on the adjacent subunit (comple-
mentary component). nAChRs contain several allosteric modulatory
sites. One such site, for positive allosteric modulators (PAMs) and al-
losteric agonists, has been proposed to reside within an intrasubunit
cavity between the four transmembrane domains [113, 375]; see
also [132]). The high resolution crystal structure of the molluscan
acetylcholine binding protein, a structural homologue of the extra-
cellular binding domain of a nicotinic receptor pentamer, in com-
plex with several nicotinic receptor ligands (e.g.[47]) and the crys-
tal structure of the extracellular domain of the α1 subunit bound
to α-bungarotoxin at 1.94 Å resolution [72], has revealed the or-
thosteric binding site in detail (reviewed in [49, 169, 291, 308]).
Nicotinic receptors at the somatic neuromuscular junction of adult
animals have the stoichiometry (α1)2β1Æ, whereas an extrajunc-
tional (α1)2β1γÆ receptor predominates in embryonic and dener-
vated skeletal muscle and other pathological states. Other nicotinic
receptors are assembled as combinations of α(2-6) and β(2-4) sub-
units. For α2, α3, α4 and β2 and β4 subunits, pairwise combinations
of α and β (e.g. α3β4 and α4β2) are sufficient to form a functional
receptor in vitro, but far more complex isoforms may exist in vivo
(reviewed in [116, 117, 236]). There is strong evidence that the
pairwise assembly of some α and β subunits can occur with variable
stoichiometry [e.g. (α4)2(β2)2 or (α4)3(β2)2] which influences the
biophysical and pharmacological properties of the receptor [236].
α5 and β3 subunits lack function when expressed alone, or pairwise,
but participate in the formation of functional hetero-oligomeric re-
ceptors when expressed as a third subunit with another α and β pair
[e.g. α4α5αβ2, α4αβ2β3, α5α6β2, see [236] for further examples].
The α6 subunit can form a functional receptor when co-expressed
with β4 in vitro, but more efficient expression ensues from incorpo-
ration of a third partner, such as β3 [366]. The α7, α8, and α9 sub-
units form functional homo-oligomers, but can also combine with
a second subunit to constitute a hetero-oligomeric assembly (e.g.
α7β2 and α9α10). For functional expression of the α10 subunit, co-
assembly withα9 is necessary. The latter, along with theα10 subunit,
appears to be largely confined to cochlear and vestibular hair cells.
Comprehensive listings of nicotinic receptor subunit combinations
identified from recombinant expression systems, or in vivo, are given
in [236]. In addition, numerous proteins interact with nicotinic ACh
receptors modifying their assembly, trafficking to and from the cell
surface, and activation by ACh (reviewed by [10, 167, 235]).
The nicotinic receptor Subcommittee of NC-IUPHAR has rec-
ommended a nomenclature and classification scheme for nicotinic
acetylcholine (nACh) receptors based on the subunit composition of
known, naturally- and/or heterologously-expressed nACh receptor
subtypes [212]. Headings for this table reflect abbreviations desig-
nating nACh receptor subtypes based on the predominant α subunit
contained in that receptor subtype. An asterisk following the indi-
cated α subunit denotes that other subunits are known to, or may,
assemble with the indicated α subunit to form the designated nACh
receptor subtype(s). Where subunit stoichiometries within a specific
nACh receptor subtype are known, numbers of a particular subunit
larger than 1 are indicated by a subscript following the subunit (en-
closed in parentheses - see also [62]).
Nomenclature
nicotinic acetylcholine
receptor α1 subunit
nicotinic acetylcholine
receptor α2 subunit
nicotinic acetylcholine
receptor α3 subunit
nicotinic acetylcholine
receptor α4 subunit
HGNC, UniProt CHRNA1, P02708 CHRNA2, Q15822 CHRNA3, P32297 CHRNA4, P43681
Commonly used
antagonists
(α1)2β1γÆ and (α1)2β1Æ:
α-bungarotoxin > pancuronium >
vecuronium > rocuronium >
tubocurarine (IC50 = 43 - 82 nM)
α2β2: DHβE (KB = 0.9 M),
tubocurarine (KB = 1.4 M); α2β4:
DHβE (KB = 3.6 M), tubocurarine (KB
= 4.2 M)
α3β2: DHβE (KB = 1.6 M, IC50 = 2.0
M), tubocurarine (KB = 2.4 M);
α3β4: DHβE (KB = 19 M, IC50 = 26
M), tubocurarine (KB = 2.2 M)
α4β2: DHβE (KB = 0.1 M; IC50 =
0.08 - 0.9 M), tubocurarine (KB =
3.2 M, IC50 = 34 M); α4β4: DHβE
(KB = 0.01 M, IC50 = 0.19 - 1.2
M), tubocurarine (KB = 0.2 M,
IC50 = 50 M)
Functional
Characteristics
(α1)2βγÆ: PCa/PNa = 0.16 - 0.2, Pf =
2.1 - 2.9%; (α1)2βÆ: PCa/PNa =
0.65 - 1.38, Pf = 4.1 - 7.2%
α2β2: PCa/PNa 1.5 α3β2: PCa/PNa = 1.5; α3β4:
PCa/PNa = 0.78 - 1.1, Pf = 2.7 - 4.6%
α4β2: PCa/PNa = 1.65, Pf = 2.6 -
2.9%; α4β4: Pf = 1.5 - 3.0 %
Selective
agonists
succinylcholine (selective for
(α1)2β1γÆ)
– – varenicline (pKi 6.6) [61], TC-2559
(α4β2) [57], rivanicline (α4β2) [270]
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(continued)
Nomenclature
nicotinic acetylcholine
receptor α1 subunit
nicotinic acetylcholine
receptor α2 subunit
nicotinic acetylcholine
receptor α3 subunit
nicotinic acetylcholine
receptor α4 subunit
Selective
antagonists
α-bungarotoxin, α-conotoxin GI,
α-conotoxin MI, pancuronium,
waglerin-1 (selective for (α1)2β1Æ)
– α-conotoxin AuIB (α3β4),
α-conotoxin MII (α3β2),
α-conotoxin PnIA (α3β2),
α-conotoxin TxIA (α3β2),
α-conotoxin-GIC (α3β2)
–
Channel blockers gallamine ((α1)2β1γÆ and (α1)2β1Æ)
(pIC50 6), mecamylamine
((α1)2β1Æ) (pIC50 5.8)
hexamethonium, mecamylamine mecamylamine (α3β4) (pIC50 6.4),
mecamylamine (α3β2) (pIC50 5.1),
A-867744 (α3β4) [222], NS1738
(α3β4) [335], hexamethonium
(α3β4), hexamethonium (α3β2)
mecamylamine (α4β2) (pIC50
5.4–5.4), mecamylamine (α4β4)
(pIC50 6.5–5.3), hexamethonium
(α4β2) (pIC50 5.2–4.5),
hexamethonium (α4β4) (pIC50 4),
A-867744 (α4β2) [222], NS1738
(α4β2) [335]
Allosteric
modulators
– LY2087101 (Positive) [37] – LY2087101 (Positive) [37]
Selective
allosteric
modulators
– – – NS9283 (Positive) [198]
Labelled ligands [125I]α-bungarotoxin (Selective
Antagonist), [3H]α-bungarotoxin
(Selective Antagonist)
[125I]epibatidine (Agonist) (pKd
11–10.7) – Rat, [3H]epibatidine
(Agonist) (pKd 11–10.7) – Rat,
[125I]epibatidine (Agonist) (pKd
10.4), [3H]epibatidine (Agonist) (pKd
10.4), [125I]epibatidine (Agonist)
(pKd 10.1–10.1) – Rat,
[3H]epibatidine (Agonist) (pKd
10.1–10.1) – Rat, [3H]cytisine
(Agonist)
[125I]epibatidine (Agonist) (pKd
11.1), [3H]epibatidine (Agonist) (pKd
11.1), [125I]epibatidine (Agonist)
(pKd 10.9–10.5) – Rat,
[3H]epibatidine (Agonist) (pKd
10.9–10.5) – Rat, [125I]epibatidine
(Agonist) (pKd 9.6), [
3H]epibatidine
(Agonist) (pKd 9.6), [
125I]epibatidine
(Agonist) (pKd 9.5–9.5) – Rat,
[3H]epibatidine (Agonist) (pKd
9.5–9.5) – Rat, [3H]cytisine (Agonist)
[125I]epibatidine (Agonist) (pKd
11–10.5), [3H]epibatidine (Agonist)
(pKd 11–10.5), [
3H]cytisine (Agonist)
(pKd 10), [
3H]cytisine (Agonist) (pKd
10) – Rat, [125I]epibatidine (Agonist)
(pKd 9.7), [
3H]epibatidine (Agonist)
(pKd 9.7), [
3H]nicotine (Agonist)
(pKd 9.4) – Rat, [
125I]epibatidine
(Agonist) (pKd 9.5–9.3) – Rat,
[3H]epibatidine (Agonist) (pKd
9.5–9.3) – Rat, [3H]cytisine (Agonist)
(pKd 9.4–9.2), [
125I]epibatidine
(Agonist) (pKd 9.1–9) – Rat,
[3H]epibatidine (Agonist) (pKd 9.1–9)
– Rat
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Nomenclature
nicotinic acetylcholine
receptor α5 subunit
nicotinic acetylcholine
receptor α6 subunit
nicotinic acetylcholine
receptor α7 subunit
HGNC, UniProt CHRNA5, P30532 CHRNA6, Q15825 CHRNA7, P36544
Commonly used
antagonists
– α6/α3β2β3 chimera: DHβE (IC50 = 1.1 M) (α7)5: DHβE (IC50 = 8 - 20 M); (α7)5: tubocurarine (IC50 = 3.1 M)
Functional
Characteristics
– – PCa/PNa = 6.6-20, Pf = 8.8 - 11.4%
Selective agonists – – encenicline (Partial agonist) (pKi 8.4) [1, 227], AQW051 ([125I]α-
bungarotoxin binding assay) (pKi 7.6) [149], 4BP-TQS (allosteric) [113],
A-582941 ((α7)5) [30], PHA-543613 ((α7)5) [359], PHA-709829 ((α7)5) [3],
PNU-282987 ((α7)5) [32], bradanicline ((α7)5) [127]
Selective antagonists α-conotoxin MII,
α-conotoxin PnIA,
α-conotoxin TxIA,
α-conotoxin-GIC
α-conotoxin MII (α6β2*), α-conotoxin MII [H9A, L15A]
(α6β2β3), α-conotoxin PIA (α6/α3β2β3 chimera)
α-bungarotoxin ((α7)5), α-conotoxin ArIB ((α7)5), α-conotoxin ImI ((α7)5),
methyllycaconitine ((α7)5)
Channel blockers – mecamylamine (α6/α3β2β3 chimera) (pIC50 5),
hexamethonium (α6/α3β2β3 chimera) (pIC50 4)
mecamylamine ((α7)5) (pIC50 4.8)
Allosteric modulators – – A-867744 (Positive) [222], LY2087101 (Positive) [37], NS1738 (Positive)
[335]
Selective allosteric
modulators
– – JNJ1930942 (Positive) [77], PNU-120596 (Positive) [148]
Labelled ligands – [3H]epibatidine (Agonist) (pKd 10.5) – Chicken,
[125I]α-conotoxin MII (Antagonist)
[3H]epibatidine (Agonist) (pKd 12.2), [
3H]A-585539 (Agonist) (pKd 10.1)
[8], [3H]AZ11637326 (Agonist) (pKd 9.6) [115], [
3H]methyllycaconitine
(Antagonist) (pKd 8.7) – Rat, [
125I]α-bungarotoxin (Selective Antagonist)
(pKd 9.1–8.3), [
3H]α-bungarotoxin (Selective Antagonist) (pKd 9.1–8.3)
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Nomenclature
nicotinic acetylcholine
receptor α8 subunit (avian)
nicotinic acetylcholine
receptor α9 subunit
nicotinic acetylcholine
receptor α10 subunit
HGNC, UniProt – CHRNA9, Q9UGM1 CHRNA10, Q9GZZ6
Commonly used
antagonists
(α8)5: α-bungarotoxin > atropine  tubocurarine
 strychnine
(α9)5: α-bungarotoxin > methyllycaconitine >
strychnine tropisetron > tubocurarine; α9α10:
α-bungarotoxin > tropisetron = strychnine >
tubocurarine
α9α10: α-bungarotoxin > tropisetron = strychnine
> tubocurarine
Functional
Characteristics
– (α9)5: PCa/PNa = 9; α9α10: PCa/PNa = 9, Pf =
22%
α9α10: PCa/PNa = 9, Pf = 22%
Selective
antagonists
– α-bungarotoxin ((α9)5), α-bungarotoxin (α9α10),
α-conotoxin RgIA (α9α10), muscarine ((α9)5),
muscarine (α9α10), nicotine (α9α10), nicotine
((α9)5), strychnine ((α9)5), strychnine (α9α10)
α-bungarotoxin (α9α10), α-conotoxin RgIA
(α9α10), muscarine (α9α10), nicotine (α9α10),
strychnine (α9α10)
Labelled ligands [3H]epibatidine ((α8)5) (pKd 9.7),
[125I]α-bungarotoxin (native α8*) (pKd 8.3),
[3H]α-bungarotoxin (native α8*) (pKd 8.3)
[3H]methyllycaconitine (Antagonist) (pKd 8.1),
[125I]α-bungarotoxin (Antagonist),
[3H]α-bungarotoxin (Antagonist)
[3H]methyllycaconitine (Antagonist) (pKd 8.1)
Nomenclature
nicotinic
acetylcholine
receptor β1 subunit
nicotinic
acetylcholine
receptor β2 subunit
nicotinic
acetylcholine
receptor β3 subunit
nicotinic
acetylcholine
receptor β4 subunit
nicotinic
acetylcholine
receptor γ subunit
nicotinic
acetylcholine
receptor Æ subunit
nicotinic
acetylcholine
receptor  subunit
HGNC, UniProt CHRNB1, P11230 CHRNB2, P17787 CHRNB3, Q05901 CHRNB4, P30926 CHRNG, P07510 CHRND, Q07001 CHRNE, Q04844
Comments Ligand interaction data for hetero-oligomeric receptors containing the β1 subunit are listed under the α1 subunits
Comments: Commonly used agonists of nACh receptors that dis-
play limited discrimination in functional assays between receptor
subtypes include A-85380, cytisine, DMPP, epibatidine, nicotine and
the natural transmitter, acetylcholine (ACh). A summary of their pro-
file across differing receptors is provided in [117] and quantitative
data across numerous assay systems are summarized in [161]. Quan-
titative data presented in the table for commonly used antagonists
and channel blockers for human receptors studied under voltage-
clamp are from [41, 52, 268, 269, 273, 360]. Type I PAMs increase
peak agonist-evoked responses but have little, or no, effect on the
rate of desensitization of α7 nicotinic ACh receptors whereas type
II PAMs also cause a large reduction in desensitization (reviewed in
[358]).
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P2X receptors
Ligand-gated ion channels! P2X receptors
Overview: P2X receptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on P2X Receptors [62, 180])
have a trimeric topology [163, 175, 254] with two putative TM do-
mains, gating primarily Na+, K+ and Ca2+, exceptionally Cl-. The
Nomenclature Subcommittee has recommended that for P2X re-
ceptors, structural criteria should be the initial criteria for nomen-
clature where possible. Functional P2X receptors exist as polymeric
transmitter-gated channels; the native receptors may occur as either
homopolymers (e.g. P2X1 in smoothmuscle) or heteropolymers (e.g.
P2X2:P2X3 in the nodose ganglion and P2X1:P2X5 in mouse cortical
astrocytes, [195]). P2X2, P2X4 and P2X7 receptors have been shown
to form functional homopolymers which, in turn, activate pores per-
meable to low molecular weight solutes [321]. The hemi-channel
pannexin-1 has been implicated in the pore formation induced by
P2X7 [274], but not P2X2 [51], receptor activation.
Nomenclature P2X1 P2X2 P2X3 P2X4
HGNC, UniProt P2RX1, P51575 P2RX2, Q9UBL9 P2RX3, P56373 P2RX4, Q99571
Agonists αβ-meATP, BzATP, L-βγ-meATP – αβ-meATP, BzATP –
Antagonists TNP-ATP (pIC50 8.9) [342], Ip5I (pIC50 8.5),
NF023 (pIC50 6.7), NF449 (pIC50 6.3) [174]
– TNP-ATP (pIC50 8.9) [342], AF353 (pIC50 8) [111],
A317491 (pIC50 7.5) [157], RO3 (pIC50 7.5) [100]
–
Selective allosteric modulators MRS 2219 (Positive) [154] – – ivermectin
(Positive) [181] –
Rat
Nomenclature P2X5 P2X6 P2X7
HGNC, UniProt P2RX5, Q93086 P2RX6, O15547 P2RX7, Q99572
Antagonists – – A804598 (pIC50 8), brilliant blue G (pIC50 8) [164], A839977 (pIC50 7.7) [81, 83, 137], A740003 (pIC50 7.4) [138],
decavanadate (pA2 = 7.4) (pA2 7.4) [234], A438079 (pIC50 6.9) [81]
Selective allosteric modulators – – chelerythrine (Negative) (pIC50 5.2) [303], AZ11645373 (Negative) [232, 318], KN62 (Negative) [110, 303], ivermectin (Positive)
[260]
Comments – – Effects of the allosteric regulators at P2X7 receptors are species-dependent.
Comments: A317491 and RO3 also block the P2X2:P2X3 hetero-
multimer [100, 157]. NF449, A317491 and RO3 are more than 10-
fold selective for P2X1 and P2X3 receptors, respectively.
Agonists listed show selectivity within recombinant P2X receptors
of ca. one order of magnitude. A804598, A839977, A740003 and
A438079 are at least 10-fold selective for P2X7 receptors and show
similar affinity across human and rodent receptors [81, 83, 137].
Several P2X receptors (particularly P2X1 and P2X3) may be inhibited
by desensitisation using stable agonists (e.g. αβ-meATP); suramin
and PPADS are non-selective antagonists at rat and human P2X1-3,5
and hP2X4, but not rP2X4,6,7 [40], and can also inhibit ATPase ac-
tivity [63]. Ip5I is inactive at rP2X2, an antagonist at rP2X3 (pIC50
5.6) and enhances agonist responses at rP2X4 [183]. Antagonist po-
tency of NF023 at recombinant P2X2, P2X3 and P2X5 is two orders
of magnitude lower than that at P2X1 receptors [315]. The P2X7
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receptor may be inhibited in a non-competitive manner by the pro-
tein kinase inhibitors KN62 and chelerythrine [303], while the p38
MAP kinase inhibitorGTPγS and the cyclic imide AZ11645373 show a
species-dependent non-competitive action [82, 232, 233, 318]. The
pH-sensitive dye used in culture media, phenol red, is also reported
to inhibit P2X1 and P2X3 containing channels [184]. Some recom-
binant P2X receptors expressed to high density bind [35S]ATPγS and
[3H]αβ-meATP, although the latter can also bind to 5’-nucleotidase
[231]. [3H]A317491 and [3H]A804598 have been used as high affin-
ity antagonist radioligands for P2X3 (and P2X2/3) and P2X7 recep-
tors, respectively [83].
Further Reading
Browne LE et al. (2011) P2X receptor channels show threefold symmetry in ionic charge selectivity and
unitary conductance. Nat. Neurosci. 14: 17-8 [PMID:21170052]
Coddou C et al. (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol. Rev.
63: 641-83 [PMID:21737531]
Collingridge GL et al. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology 56: 2-5
[PMID:18655795]
Kaczmarek-Hájek K et al. (2012) Molecular and functional properties of P2X receptors–recent progress
and persisting challenges. Purinergic Signal. 8: 375-417 [PMID:22547202]
Khakh BS et al. (2001) International union of pharmacology. XXIV. Current status of the nomenclature
and properties of P2X receptors and their subunits. Pharmacol. Rev. 53: 107-18 [PMID:11171941]
Khakh BS et al. (2012) Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 76:
51-69 [PMID:23040806]
North RA et al. (2013) P2X receptors as drug targets. Mol. Pharmacol. 83: 759-69 [PMID:23253448]
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Ryanodine receptor
Ligand-gated ion channels! Ryanodine receptor
Overview: The ryanodine receptors (RyRs) are found on intracellu-
lar Ca2+ storage/release organelles. The family of RyR genes encodes
three highly related Ca2+ release channels: RyR1, RyR2 and RyR3,
which assemble as large tetrameric structures. These RyR channels
are ubiquitously expressed in many types of cells and participate in
a variety of important Ca2+ signaling phenomena (neurotransmis-
sion, secretion, etc.). In addition to the three mammalian isoforms
described below, various nonmammalian isoforms of the ryanodine
receptor have been identified [323]. The function of the ryanodine
receptor channels may also be influenced by closely associated pro-
teins such as the tacrolimus (FK506)-binding protein, calmodulin
[365], triadin, calsequestrin, junctin and sorcin, and by protein ki-
nases and phosphatases.
Nomenclature RyR1 RyR2 RyR3
HGNC, UniProt RYR1, P21817 RYR2, Q92736 RYR3, Q15413
Functional Characteristics Ca2+: (P Ca/P K 6) single-channel conductance:
90 pS (50mM Ca2+), 770 pS (200 mM K+)
Ca2+: (P Ca/P K 6) single-channel conductance:
90 pS (50mM Ca2+), 720 pS (210 mM K+)
Ca2+: (P Ca/P K 6) single-channel conductance:
140 pS (50mM Ca2+), 777 pS (250 mM K+)
Endogenous activators cytosolic ATP (endogenous; mM range), cytosolic
Ca2+ (endogenous; M range), luminal Ca2+
(endogenous)
cytosolic ATP (endogenous; mM range), cytosolic
Ca2+ (endogenous; M range), luminal Ca2+
(endogenous)
cytosolic ATP (endogenous; mM range), cytosolic
Ca2+ (endogenous; M range)
Activators caffeine (pharmacological; mM range), ryanodine
(pharmacological; nM - M range), suramin
(pharmacological; M range)
caffeine (pharmacological; mM range), ryanodine
(pharmacological; nM - M range), suramin
(pharmacological; M range)
caffeine (pharmacological; mM range), ryanodine
(pharmacological; nM - M range)
Endogenous antagonists cytosolic Ca2+ Concentration range: >110 4M,
cytosolic Mg2+ (mM range)
cytosolic Ca2+ Concentration range: >110 3M,
cytosolic Mg2+ (mM range)
cytosolic Ca2+ Concentration range: >110 3M,
cytosolic Mg2+ (mM range)
Antagonists dantrolene – dantrolene
Channel blockers procaine, ruthenium red, ryanodine Concentration
range: >110 4M
procaine, ruthenium red, ryanodine Concentration
range: >110 4M
ruthenium red
Comments RyR1 is also activated by depolarisation via DHP
receptor, calmodulin at low cytosolic Ca2+
concentrations, CaM kinase and PKA; antagonised
by calmodulin at high cytosolic Ca2+
concentrations
RyR2 is also activated by CaM kinase and PKA;
antagonised by calmodulin at high cytosolic Ca2+
concentrations
RyR3 is also activated by calmodulin at low
cytosolic Ca2+ concentrations; antagonised by
calmodulin at high cytosolic Ca2+ concentrations
Comments: The modulators of channel function included in this table are those most commonly used to identify ryanodine-sensitive Ca2+ release pathways. Numerous other modulators of ryanodine recep-
tor/channel function can be found in the reviews listed below. The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is
without effect. The potential role of cyclic ADP ribose as an endogenous regulator of ryanodine receptor channels is controversial. A region of RyR likely to be involved in ion translocation and selection has been
identified [107, 381].
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ZAC
Ligand-gated ion channels! ZAC
Overview: The zinc-activated channel (ZAC, nomenclature as agreed by the NC-IUPHAR Subcommittee for the Zinc Activated Channel) is a member of the Cys-loop family that includes the
nicotinic acetylcholine, 5-HT3, GABAA and strychnine-sensitive glycine receptors [69, 143]. The channel is likely to exist as a homopentamer of 4TM subunits that form an intrinsic cation selective channel displaying
constitutive activity that can be blocked by tubocurarine. ZAC is present in the human, chimpanzee, dog, cow and opossum genomes, but is functionally absent from mouse, or rat, genomes [69, 143].
Nomenclature ZAC
HGNC, UniProt ZACN, Q401N2
Functional Characteristics Outwardly rectifying current (both constitutive and evoked by Zn2+)
Endogenous agonists Zn2+ (Selective) (pEC50 3.3) [69]
Selective antagonists tubocurarine (pIC50 5.2) [69]
Comments Although tabulated as an antagonist, it is possible that tubocurarine acts as a channel blocker.
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